

PATENT
USSN 09/732,348
674538-2001

REMARKS

Reconsideration and withdrawal of the rejections of this application, and reconsideration and withdrawal of the restriction requirement, and, if necessary, an early interview with the Examiner and SPE Amy Nelson, are respectfully requested in view of the amendments and remarks and attachments herewith.

**THE NEW CLAIMS,
THE SPECIFICATION AMENDMENT,
AND THAT THE RESTRICTION REQUIREMENT REMAINS IMPROPER,
AND PETITION FOR WITHDRAWAL OF THE RESTRICTION REQUIREMENT**

The application, at pages 1-2 and 11-12, is amended to correct obvious typographical errors. No new matter is added.

Claims 24-70 are now pending. These claims include claims directed to the elected subject matter, with traverse, of previous claims 7, 8, 10-15 and 17-22, e.g., claims 24-42, 44-48, and are based on the application as originally-filed, including the original claims, Examples and description, especially the description at pages 8-19. No new matter is added. The subject matter of claims 1-6, 9, 16 and 23 remain pending in claims 43 and 51-70 as it is respectfully asserted that the restriction requirement was improper and the assertion in support of it in the Office Action is also improper.

It is submitted that the claims herewith and those that were previously pending are patentably distinct from the references cited by the Examiner, and that these claims are in full compliance with the requirements of 35 U.S.C. §112.

In addition, the Examiner is thanked for considering the documents filed with Applicants' IDS forms.

As to the restriction requirement, the Office Action asserts that the MPEP is controlling and asserts that an application may be restricted to one of two or more claimed inventions "if they are independent *or* distinct" (emphasis in original, citing MPEP 803). The Office Action, it is respectfully submitted, is incorrect in asserting that the MPEP is controlling.

The Statute, 35 USC, and the Rules of the Director promulgated pursuant thereto, are controlling. 37 CFR 1.141(a) provides that two or more "independent and distinct inventions

PATENT
USSN 09/732,348
674538-2001

may not be claimed in one national application ..." (emphasis added). Similarly, 35 USC 121 states: "If two or more independent and distinct inventions are claimed in one application, the Director may require the application to be restricted to one of the inventions ..." (emphasis added).

Clearly, it is respectfully asserted that the Director, and hence the Examiner, **HAS NO AUTHORITY TO DO AS STATED IN THE OFFICE ACTION.**

Simply, the assertion that "an application may be properly required to be restricted to one of two or more claimed inventions if they are either independent *or* distinct" is **NOT CORRECT AS IT IS CONTRARY TO THE EXPRESS LANGUAGE OF THE STATUTE FROM WHICH THE DIRECTOR AND HENCE THE EXAMINER DERIVE THEIR AUTHORITY TO RESTRICT.** The MPEP is not the law: The Statute and the Rules are the law; and, the Director, and hence the Examiner, must follow the Statute and the Rules, instead of the MPEP, if the MPEP is inconsistent with the Statute and the Rules.

Therefore, this paper renews the request for reconsideration and withdrawal of the restriction requirement **and petitions for reconsideration and withdrawal of the restriction requirement, with any requisite fee therefor or any overpayment in fees to be charged or credited to Deposit Account No. 50-0320.**

The arguments in the August 16, 2002 Communication In Response To Office Action Containing Restriction Requirement, incorporated herein by reference, and the herein arguments, are respectfully asserted in support of reconsideration and withdrawal of the restriction requirement and the herein petition for reconsideration and withdrawal of the restriction requirement.

Moreover, certain of the arguments raised in the August 16, 2002 Communication, it is respectfully submitted, were not fully or properly considered or rebutted. For this reason too, it is respectfully requested that, in reconsidering the restriction requirement, the August 16, 2002 Response be fully and properly considered.

For instance, and as stated in Applicants' August 16 response, the subject matter of Groups I and III, on the one hand, and Groups II and IV on the other, do not have different effects; they both involve regulation of transcription. Activation and repression are two manifestations of transcriptional regulation. The Office Action states that activation and

PATENT
USSN 09/732,348
674538-2001

repression domains have different modes of operation because they require the presence and use of different polypeptides and polynucleotides for operation. This argument is not found persuasive by Applicants because the process of transcriptional activation, by itself, can involve different polypeptides and/or polynucleotides, depending upon the gene which is being activated and other factors *e.g.*, cell type and state of development. Similarly, repression of different genes can involve different polypeptides and/or polynucleotides. In addition, production of a transcript from a gene can be repressed by one or more proteins, while levels of the transcription product (*i.e.* mRNA levels) can be regulated by small RNAs such as RNAi molecules, and both the proteins which repress transcription, and the small RNA molecules which reduce transcript levels, can be different for different genes. Indeed, small RNA repressors of transcript levels would have to be different for different genes, since they function by base-pairing to the transcript. Thus, the distinction that is being made between transcriptional activation and transcriptional repression, in the Restriction Requirement, is an artificial one and is not credible. In the same way that a credible utility for an invention is required by an Applicant; so also must the Office, when it asserts that two sets of claims represent separate "inventions," provide credible utilities for all of the alleged different inventions.

Thus, it is respectfully submitted that it is not proper to restrict between activating and repressing transcription (*i.e.*, between Group I and II; and between Group III and IV).

With respect to the restriction between Groups I and II, Applicants note that, in the restriction requirement, the Examiner stated that the methods of groups I and II were not used together. Applicants replied, in their Response of August 16, that the methods of Groups I and II could be used together and provided an example of the simultaneous use of the methods of Groups I and II. In the Office Action, the Examiner makes no reply to these arguments, other than to make a conclusory statement which simply repeats the assertion set forth in the original Restriction requirement that the methods could not be used together. Hence, the Examiner has failed to rebut Applicants' arguments and, for this reason, Applicants believe that the restriction between Groups I and II is improper and should be withdrawn.

Furthermore, the subject matters of Groups I-IV have the same mode of operation, namely the regulation of gene expression, regardless of whether the zinc finger protein is introduced into the cell as a protein, or the cell comprises a polynucleotide encoding an

PATENT
USSN 09/732,348
674538-2001

engineered zinc finger protein from which the zinc finger polypeptide is expressed. In both cases, a zinc finger polypeptide is present in the cell and regulates gene expression. Thus, it is respectfully submitted that there is no basis for restricting between claims involving introducing an engineered zinc finger polypeptide into a cell and claims involving a cell comprising a polynucleotide encoding an engineered zinc finger polypeptide.

Finally, the July 16 Restriction Requirement states that the host cells and transgenic plants of Groups III and IV comprise structurally and functionally distinct polynucleotides. Applicants respectfully traverse this assertion, since it is well-known that all polynucleotides are structurally similar, comprising the four nucleotides A, G, C and T, and the polynucleotides of Groups III and IV are functionally similar in that they encode proteins which regulate gene expression.

Therefore, it is respectfully submitted that when the Statute, Rules, previous arguments of the August 16, 2002 Communication and the arguments presented herein are properly and fully considered, the restriction requirement cannot stand and should be reconsidered and withdrawn, with such relief herein respectfully requested by way of petition.

Accordingly, examination on the merits and allowance of all of the claims now pending are respectfully requested.

THE SECTION 112, 2ND PARAGRAPH REJECTION IS OVERCOME

Claims were rejected under 35 USC 112 (*Office Action* at 8). Applicants respectfully traverse, as the terms mentioned in the Office Action are defined and discussed in the specification.

As to "engineered", attention is respectfully directed to page 3, lines 15-17, page 4, line 22 to page 5, line 3, and page 9, lines 14-17, where this term is discussed.

Likewise, "biological effector domain" is defined at page 6, lines 6-9 as a "polypeptide that has a biological function and includes enzymes and transcriptional regulatory domains or proteins, and additional sequence[s] such as nuclear localization sequences."

Accordingly, reconsideration and withdrawal, of the Section 112, second paragraph rejection, are respectfully requested.

PATENT
USSN 09/732,348
674538-2001

THE SECTION 112, 1st PARAGRAPH REJECTIONS ARE OVERCOME

Claims were rejected under 35 USC 112, first paragraph (*Office Action* at 3-7), with the Office Action essentially asserting that only certain exemplified embodiments are described and enabled (*Office Action* at 4, 5). These rejections are a written description rejection and a lack of enablement rejection; and, these rejections shall be addressed collectively.

There Is Indeed Written Description For The Claimed Subject Matter

The test for whether there is an adequate written description is whether the application as filed evinces possession of the subject matter claimed by the Applicants. *See* Written Description Guidelines, Fed. Reg. 66(4): 1099-1111 (Jan. 5, 2001).

Against this background, the Examiner's attention is respectfully directed to the numerous documents of record, the documents cited herein and submitted herewith, and the text in the present application, especially in the Examples, the original claims and at pages 8-19; and, it is respectfully submitted that close attention may be paid to the text at pages 8-19 and the documents cited thereat (which are also incorporated by reference into the instant application) in comparison with the claims.

Text of the present claims closely parallels the text at pages 8-19.

The text at pages 8-19 teaches numerous zinc finger polypeptides of the claimed subject matter. From that teaching, and the text at page 28 *et seq.*, the present application also teaches polynucleotides encoding the numerous disclosed zinc finger polypeptides. In this regard, attention is also respectfully directed to page 50, line 20 to page 51, line 2 and Example 5 of the instant application, which also provides further description of the claimed subject matter.

Thus, there was clearly possession of the claimed subject matter at the time of filing, and there is clearly a written description of the claimed subject matter in the present application, especially when one carefully considers the text of the instant application and that all documents cited in the instant application are incorporated by reference into the instant application, as if set out in full, such that the description in the instant application includes the text of all of the documents cited in the instant application (which were cited to the Examiner in previously-filed IDSs).

Simply, when the specification is properly considered, including when it is considered in the light of the documents incorporated by reference into it and in the light of the knowledge in

PATENT
USSN 09/732,348
674538-2001

the art, it is clear that Applicants had possession of the claimed subject matter.

Thus, it is also stated that pursuant to MPEP 2144.03, Applicants are seasonably challenging the statements in the Office Action made with respect to the Section 112, first paragraph rejections, especially because it is respectfully submitted that the record in the instant application illustrates that one skilled in the art would recognize Applicants' possession of the claimed subject matter.

Accordingly, reconsideration and withdrawal of the Section 112, first paragraph, written description rejection, are respectfully requested.

There Is Indeed Enablement For The Claimed Subject Matter

As to enablement, the Examiner is respectfully directed to the case law.

In regard to the Section 112 rejections, the Examiner is respectfully reminded that she bears the burden in making a Section 112, first paragraph, rejection, to establish a reasonable basis to question the enablement or scope provided for the claimed subject matter. *In re Wright*, 999 F.2d 1557, 27 USPQ2d 1510 (Fed. Cir. 1993) (examiner must provide a reasonable explanation as to why the scope of protection provided by a claim is not adequately enabled by the disclosure); and, that a specification disclosure which contains a teaching of the manner and process of making and using claimed subject matter in terms which correspond in scope to those used in describing and defining the subject matter sought to be patented (i.e., the claim language) must be taken as being in compliance with 35 USC 112, first paragraph, unless there is a reason to doubt the objective truth of the statements contained in the application.

According to the Court of Appeals for the Federal Circuit in the case of *In re Wands*, 8 USPQ2d 1400 (Fed. Cir. 1988),

Enablement is not precluded by the necessity for some experimentation such as routine screening. However, experimentation needed to practice the invention must not be undue experimentation. 'The key word is undue, not experimentation.' The determination of what constitutes undue experimentation in a given case requires the application of standard of reasonableness, having due regard for the nature of the invention and the state of the art. The test is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed ... [Citations omitted].

PATENT
USSN 09/732,348
674538-2001

Id. at 1404.

Determining whether undue experimentation is required to practice a claimed subject matter turns on weighing many factors summarized in *In re Wands*, 858 F.2d 731, 8 USPQ2d 1400 (Fed. Cir. 1988), for example: (1) the quantity of experimentation necessary; (2) the amount of direction or guidance presented; (3) the presence or absence of working examples of the claimed subject matter; (4) the nature of the claimed subject matter; (5) the state of the prior art; (6) the relative skill of those in the art; (7) the predictability or unpredictability of the art; and (8) the breadth of the claims.

Thus, it is respectfully submitted that for a proper Section 112, first paragraph, lack of enablement analysis, an Office Action must show that the *Wands* factors are not met. Simply, it is respectfully asserted that the lack of enablement rejection fails to provide a fact based analysis using the *Wands* factors that supports the proposition the claimed subject matter requires undue experimentation. In view of this, it is respectfully urged that since the rejection does not provide any evidence to establish a *prima facie* case of non-enablement, the Section 112, first paragraph rejection must *prima facie*, fail. See *In re Marzocchi*, 169 USPQ 367, 369-70 (CCPA 1971) (when the PTO makes a rejection based on enablement the Examiner must support the rejection with acceptable evidence); see also, MPEP 2164.04.

The Examiner is also respectfully reminded that a specification need not contain any example of the claimed subject matter, as the issue is whether the disclosure enables one skilled in the art to practice the claimed subject matter without undue experimentation. *In re Borkowski*, 422 F.2d 904, 164 USPQ 642 (CCPA 1970). And, the Examiner is further respectfully reminded that an applicant need not describe all actual embodiments of the claimed subject matter.

The first paragraph of Section 112 does not require a specific example of everything within the scope of a broad claim. *In re Anderson*, 176 USPQ. 331, 333 (CCPA 1973). This is true even in an unpredictable art. *In re Obukowitz*, 27 U.S.P.Q. 2d 1063, 1067 (BPAI 1993).

Indeed, such a requirement would have an adverse affect on the patent system. See *In re Angstadt and Griffin*, 190 USPQ 214, 218 (CCPA 1976) (to require a disclosure of every species covered by a claim would force an inventor to carry out a prohibitive number of experiments, and would allow potential infringers to avoid literal infringement by merely finding an analogous embodiment not expressly disclosed)); *In re Goffe*, 191 USPQ 429, 431 ("To demand that the first

PATENT
USSN 09/732,348
674538-2001

to disclose shall limit his claims to what he has found will work or to materials which meet the guidelines specified for 'preferred' materials in a process would not serve the constitutional purpose of promoting progress in the useful arts.”).

Thus, it is respectfully submitted that, it is improper to endeavor to limit Applicants to only exemplified embodiments.

Moreover, as previously mentioned, text of the present claims closely parallels the text at pages 8-19.

Again, the text at pages 8-19 teaches numerous zinc finger polypeptides of the claimed subject matter.

From the teachings at pages 8-19, and the text at page 28 *et seq.*, the present application also teaches polynucleotides encoding the numerous disclosed zinc finger polypeptides.

Furthermore, the text at page 50, line 20 to page 51, line 2 and the teachings in Example 5 of the instant application, when fully considered with the text at pages 8-19 and the text at page 28 *et seq.*, and with the documents cited in and incorporated by reference into the present application, clearly shows that no undue experimentation is needed to practice the claimed subject matter.

Against this request that the art cited herein and herewith be considered and made of record, and that documents that are already of record be further considered to show the level of knowledge and skill in the art, it is respectfully asserted that the *Wands* factors weigh in Applicants favor.

With respect to the quantity of experimentation necessary, the vast body of literature and the detailed description and Examples in the application demonstrate that no undue experimentation is needed to practice the claimed subject matter.

As to the amount of direction or guidance presented, the present application is very detailed in its description, especially when one considers the numerous embodiments described and enabled, particularly when the documents cited and incorporated by reference into the present application are fully considered in conjunction with the teachings in the instant application.

With regard to the presence or absence of working examples of the claimed subject matter, as noted in the Office Action and herein, the present application includes working

PATENT
USSN 09/732,348
674538-2001

examples. The claimed subject matter involves the expression and operation of engineered zinc finger polypeptides in plants: something that the skilled artisan can indeed work in view of the teachings in the present application and the level of skill in the art at the effective filing date of the present application.

As discussed above, the state of the art is that the art of zinc finger polypeptides is developed. The skilled artisan is highly skilled, e.g., a Ph.D. The art is reasonably predictable. And, the claims are commensurate in scope with Applicants' contribution to the art, especially when one considers that the present claims are patentable over the prior art under 35 USC 102 and 103.

Thus, when a proper *Wands* analysis is performed, it is clear that the presently claimed subject matter is fully enabled.

Further still, as a housekeeping matter that is additional to the foregoing assertion that the Office Action failed to supply a proper *Wands* analysis in support of the Section 112, first paragraph, lack of enablement rejection, the Examiner is respectfully invited to support her assertion that "in view of the level of knowledge and skill in the art, one skilled in the art would not recognize from the disclosure that the Applicant was in possession of the genus that comprises polynucleotides encoding engineered zinc finger polypeptides ..."

That is, pursuant to MPEP 2144.03, Applicants are seasonably challenging the statements in the Office Action made with respect to the Section 112, first paragraph rejections, especially because it is respectfully submitted that the record in the instant application illustrates that no undue experimentation is required to practice the claimed subject matter.

Simply, as with the written description rejection, it is respectfully submitted that mere Examiner argument is insufficient as the Statute mandates the granting of a patent to Applicants unless the Examiner can show failure to comply with the statutory requirements by at least a preponderance of the evidence.

Accordingly, when the specification is properly considered, including when it is considered in the light of the documents incorporated by reference into it and in the light of the knowledge in the art, it is clear that no undue experimentation is needed to practice the claimed subject matter.

Therefore, reconsideration and withdrawal of the Section 112, first paragraph, lack of

PATENT
USSN 09/732,348
674538-2001

enablement rejection are respectfully requested.

THE CLAIMS ARE PATENTABLE OVER THE CITED ART

Claims 7-8, 10-12 and 17-19 were rejected under 35 USC 102(b) as allegedly anticipated by Putterill et al., Cell 80:847-857 (1995), and claims 7-8, 10-11, 13-15, 17-18 and 20-22 were rejected as allegedly anticipated by Aoyama et al., The Plant Journal 11(3):605-12 (1997). These rejections shall be addressed collectively and are respectfully traversed, because neither Putterill nor Aoyama teach or suggest an engineered zinc finger polypeptide as disclosed in the present application.

Independent claims 24 and 51 recite an "engineered" zinc finger polypeptide. See, for example page 3, lines 15-17, page 4, line 22 to page 5, line 3, and page 9, lines 14-17, where this term "engineered" is discussed.¹

In contrast to the meaning of "engineered" set forth in the specification, the putative zinc finger polypeptide in Putterill is nothing more than a cloned, naturally-occurring zinc finger polypeptide, and does not correspond to, teach or suggest an engineered zinc finger polypeptide as recited in the presently-pending claims. Accordingly, Putterill fails to disclose each and every element of the claimed subject matter, and is therefore not an appropriate §102 reference.

Moreover, there is no basis for the assertion in the Office Action that the putative zinc finger polypeptide in Putterill would inherently regulate transcription of an endogenous coding sequence.

Indeed, it is well known that different zinc finger polypeptides are capable of binding to DNA, RNA and/or proteins. Further still, submitted herewith is an Abstract by Putterill et al. (submitted herewith) from the 8th International Meeting on Arabidopsis Research, June 25-29, 1997, Madison, Wisconsin, Abstract 3-58 available on the internet at www.arabidopsis.org/madison97/at97abs/imar_3-58.html where it seems that, as to the subject matter of the Putterill article cited in the Office Action, Putterill state that how COL1 (67% identical to CO and part of the CO family of proteins of the Putterill article cited in the Office Action) influences flowering at the molecular level is unknown.

¹ The meaning of the term engineered is also discussed *supra*, in the section concerning 35 U.S.C. § 112, second paragraph.

PATENT
USSN 09/732,348
674538-2001

Further still, in 2001 Robson et al, The Plant Journal 28(6):619-631 (2001) (submitted herewith)² state that, as to the putative zinc finger polypeptide of the Putterill article cited in the Office Action, Putterill observed "an arrangement of cysteine residues similar to that present in the zinc fingers of GATA transcription factors, **but little direct homology to these proteins was detected**" (emphasis added). Robson continues by showing that the Putterill putative zinc finger polypeptide likely **does not** regulate transcription of an endogenous coding sequence; but rather, is a B-box containing protein with a RBCC motif that mediates protein-protein interaction, rather than DNA binding.

Therefore, it is respectfully submitted that the assertion in the Office Action as to Putterill is incorrect: the putative zinc finger polypeptide of Putterill does not inherently target endogenous DNA sequences, especially as shown by Robson.

On this point, and as to both of the Section 102 rejections, the Examiner is respectfully directed to *In re Wilson*, 165 USPQ 494, 496 (CCPA 1970) and *Cont'l Can Co. v. Monsanto Co.*, 20 USPQ2d 1746, 1749 (Fed. Cir. 1991) which are cited for the propositions that all words in the claims must be fully considered in assessing patentability; and, that inherency cannot be established by probabilities or possibilities. Furthermore, it is respectfully pointed out that for a Section 102 rejection to stand, the prior art reference must contain all of the elements of the claimed subject matter, *see Lewmar Marine Inc. v. Barient Inc.*, 3 U.S.P.Q.2d 1766 (Fed. Cir. 1987).

Clearly, the mere speculation in the Office Action as to the mode of action of the putative zinc finger in Putterill is insufficient to establish inherency because mere probabilities or possibilities cannot establish inherency; moreover, the mere speculation in the Office Action as to the mode of action of the putative zinc finger in Putterill is clearly insufficient in view of Putterill's 1997 Abstract and the 2001 Robson article which disprove the theory set forth in the Office Action.

Aoyama is cited as allegedly providing a tobacco plant host cell and transgenic tobacco

² The Examiner is respectfully requested to consider and make of record Abstract by Putterill et al. from the 8th International Meeting on Arabidopsis Research, June 25-29, 1997, Madison, Wisconsin, Abstract 3-58 available on the internet at www.arabidopsis.org/madison97/at97abs/imar_3-58.html and Robson et al, The Plant Journal 28(6):619-631 (2001). A PTO-1449 in duplicate is submitted herewith. As these documents are submitted in support of patentability, it is believed that no fee should be due for considering and making them of record; but, any fee therefor or any overpayment in fees may be charged or credited to Deposit Account No. 50-0320.

PATENT
USSN 09/732,348
674538-2001

plant having a polynucleotide encoding a GAL4 zinc finger polypeptide fused to a VP16 biological effector domain and a GR transcriptional activator domain, and a heterologous GAL4 UAS target DNA sequence to which the zinc finger polypeptide binds, with the target DNA sequence allegedly being operably linked to a heterologous LUC coding sequence whose transcription is allegedly regulated by binding of the zinc finger polypeptide to the target sequence.

The zinc finger portion of Aoyama's fusion comprises a naturally-occurring GAL4 zinc finger polypeptide. Accordingly, and like Putterill, Aoyama fails to teach or suggest an engineered zinc finger polypeptide as disclosed in the present application, for example at page 3, lines 15-17, page 4, line 22 to page 5, line 3, and page 9, lines 14-17, where this term "engineered" is discussed.

Thus, each of Putterill and Aoyama individually fail to provide a teaching of all of the elements of each of the claims. Therefore, in view of the case law, neither of Putterill and Aoyama is sufficient for making a Section 102 rejection. Furthermore, there is no teaching, suggestion, incentive or motivation to modify Putterill or Aoyama.

Accordingly, neither Aoyama nor Putterill, either individually or in any combination, teaches or suggests the presently claimed subject matter. In this regard, the Examiner is respectfully requested to fully consider each recitation of each claim as the claims do not stand or fall together.

Reconsideration and withdrawal of the Section 102 rejections are respectfully requested.

REQUEST FOR INTERVIEW

If any issue remains as an impediment to allowance, prior to issuance of any paper other than a Notice of Allowance, an interview is respectfully requested, with the Examiner and her SPE, Amy Nelson; and, the Examiner is respectfully requested to contact the undersigned to arrange a mutually convenient time and manner for such an interview.

CONCLUSION

In view of the amendments, remarks and documents herewith, Applicants have addressed and overcome all rejections of the application set forth in the Office Action, as well as the restriction requirement, and the present application is in condition for allowance.


PATENT
USSN 09/732,348
674538-2001

Thus, early and favorable reconsideration and withdrawal of the rejections of the application as set forth in the Office Action, and, prompt issuance of a Notice of Allowance of claims 24-70, or an interview with supervisory review, i.e., an interview including SPE Amy Nelson, at an early date, with a view towards reaching agreement on allowable subject matter, are earnestly solicited.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP
Attorneys for Applicants

By:



Thomas J. Kowalski, Reg. No. 32,147
Tel 212-588-0800
Fax 212-588-0500

PATENT
USSN 09/732,348
674538-2001

APPENDIX: MARKED VERSION OF AMENDMENT

Please amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

IN THE SPECIFICATION

Please amend the specification, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

Page 1, line 5 to page 2, line 12:

This application is a continuation-in-part of PCT application no. PCT/GB00/02071 entitled "GENE SWITCHES" filed 30 May 2000 and published on December 7, 2000 as WO 00/73434, designating the US and claiming priority from GB applications 9912635.1 filed [18]28 May 1999 and Great Britain applications [001580.0 and 001578.4] 0001580.0 and 0001578.4, both of which were filed 24 January 2000. Further mentioned and incorporated by reference herein are PCT/GB99/03730, filed November 9, 1999, published as WO00/27878A1 on May 18, 2000 entitled "Screening System For Zinc Finger Polypeptides For A Desired Binding Ability" and claiming priority from GB application 9824544.2, filed November 9, 1998, and designating the US; PCT/GB99/03730 which is a continuation-in-part of US patent application Serial No. 09/139, 762, filed August 25, 1998 (now US Patent No. 6,013,453), which is a continuation of US patent application Serial No. 08/793,408 (now US Patent No. 6,007,988), filed as PCT application no. PCT/GB95/01949 on August 17, 1995, designating the U.S. and, published as WO96/06166 on February 29, 1996 entitled "Improvements in or Relating to Binding Proteins for Recognition of DNA"; PCT/GB95/01949 claims the benefit of priority from GB application 9514698.1, filed July 18, 1995, GB application 9422534.9, filed November 8, 1994 and GB application no. 9416880.4, filed August 20, 1994. Mention is also made of: USSN 08/422,107; WO96/32475; WO99/47656A2, published September 23, 1999 entitled "Nucleic Acid Binding Proteins"; WO98/53060A1, published November 26, 1998 entitled "Nucleic Acid Binding Proteins"; WO98/53059A1 published November 26, 1998 entitled "Nucleic Acid Binding Proteins"; WO98/53058A1 published November 26, 1998 entitled "Nucleic Acid Binding Proteins"; WO98/53057A1 published November 26, 1998 (entitled "Nucleic Acid Binding Polypeptide Library"); US Patent Nos. 6,013,453 and 6,007,988; Fiehn et al. (2000) Nature Biotechnol. 18:1157-1161; Richter et al. (2000) Nature Biotechnol. 18:1167-1171; and,

PATENT
 USSN 09/732,348
 674538-2001

generally, Nature Biotechnol. Vol. 18(11) together with all documents cited or referenced therein. Each of the foregoing applications and patents, and each document cited or referenced in each of the foregoing applications and patents, including during the prosecution of each of the foregoing applications and patents ("application cited documents") and any manufacturer's instructions or catalogues for any products cited or mentioned in each of the foregoing applications and patents and in any of the application cited documents, are hereby incorporated herein by reference. Furthermore, all documents cited in this text, and all documents cited or referenced in documents cited in this text, and any manufacturer's instructions or catalogues for any products cited or mentioned in this text, are hereby incorporated herein by reference.

Pages 11-12, please rewrite the text of the second full paragraph on page 11 and the paragraph bridging pages 11-12, and the first full paragraph on page 12 as follows:

--In general, a preferred zinc finger framework has the structure:

(A) $[X_{0-2} C X_{1-5} C X_{9-14} H X_{3-6} H/C] \underline{X_{0-2} C X_{1-5} C X_{9-14} H X_{3-6} H/C}$

where X is any amino acid, and the numbers in subscript indicate the possible numbers of residues represented by X.

In a preferred aspect of the present invention, zinc finger nucleic acid binding motifs may be represented as motifs having the following primary structure:

(B) $\underline{X^a C X_{2-4} C X_{2-3} F X^c X X X X L X X H X X X^b H}$ - linker

$[X_a C X_{2-4} C X_{2-3} F X_c X X X X L X X H X X X_b H]$ - linker

-1 1 2 3 4 5 6 7 8 9]

wherein X (including X^a , X^b and X^c) is any amino acid. X_{2-4} and X_{2-3} refer to the presence of 2 or 4, or 2 or 3, amino acids, respectively, and $\underline{X X X X L X X H X X}$ between X^c and X^b are designated positions -1, 1, 2, 3, 4, 5, 6, 7, 8, and 9. The Cys and His residues, which together coordinate the zinc metal atom, are marked in bold text and are usually invariant, as is the Leu residue at position +4 in the α -helix.

Modifications to this representation may occur or be effected without necessarily abolishing zinc finger function, by insertion, mutation or deletion of amino acids. For example it is known that the second His residue may be replaced by Cys (Krizek *et al.*, (1991) J. Am. Chem. Soc. 113:4518-4523) and that Leu at +4 can in some circumstances be replaced with Arg. The Phe residue before $\underline{X^c}$ [X_c] may be replaced by any aromatic other than Trp. Moreover,

PATENT
USSN 09/732,348
674538-2001


experiments have shown that departure from the preferred structure and residue assignments for the zinc finger are tolerated and may even prove beneficial in binding to certain nucleic acid sequences. Even taking this into account, however, the general structure involving an α -helix coordinated by a zinc atom which contacts four Cys or His residues, does not alter. As used herein, structures (A) and (B) above are taken as an exemplary structure representing all zinc finger structures of the Cys₂-His₂ [Cys2-His2] type.--

PATENT
 USSN 09/732,348
 674538-2001

CLAIMS NOW PENDING


24. (New) A plant host cell or transgenic plant comprising a polynucleotide encoding an engineered zinc finger polypeptide and a target DNA sequence to which the zinc finger polypeptide binds.

25. (New) The plant host cell or transgenic plant of claim 24, wherein the zinc finger polypeptide has two or more zinc fingers and the zinc fingers have structures of the formula



wherein X is any amino acid and the numbers in subscript indicate possible numbers of residues represented by X.

26. (New) The plant host cell or transgenic plant of claim 25 wherein the zinc finger structures have a binding motif represented by:



wherein each of X, X^a, X^b, X^c is any amino acid, the numbers in subscript indicate possible numbers of residues, and X X X X L X X H X X between X^c and X^b are designated positions -1, 1, 2, 3, 4, 5, 6, 7, 8, and 9.

27. (New) The plant host cell or transgenic plant of claim 26 wherein X^a is E, K, T, S, Q, V, A or P, X^b is T or I, X^c is S or T, X₂₋₄ is two amino acids, with the first of which being S, E, K, T, P, or R, and the second amino acid being E, and the linker is T-G-E-K or T-G-E-K-P, and position 9 is Arg or Lys, and positions 1, 5, and 8 are hydrophobic amino acids and not Phe, Trp or Tyr.

28. (New) The plant host cell or transgenic plant of claim 26 wherein one or more of the zinc fingers binds to a target DNA triplet in accordance with the following:

(a) if the 5' base in the triplet is G, then position 6 is Arg or position ++2 is Asp or position 6 is Arg and position 2 is Asp;

(b) if the 5' base in the triplet is A, then position 6 is Gln or Glu and ++2 is not Asp;

(c) if the 5' base in the triplet is T, then position 6 is Ser or Thr and position ++2 is Asp or position 6 is a hydrophobic amino acid other than Ala;

(d) if the 5' base in the triplet is C, then position 6 may be any amino acid, provided that position ++2 is not Asp;

(e) if the central base in the triplet is G, then position 3 is His;

PATENT
USSN 09/732,348
674538-2001

- (f) if the central base in the triplet is A, then position 3 is Asn;
 - (g) if the central base in the triplet is T, then position 3 is Ala, Ser, Ile, Leu, Thr or Val provided that if it is Ala, then one of the residues at -1 or 6 is a small residue;
 - (h) if the central base in the triplet is 5-meC, then position 3 is Ala, Ser, Ile, Leu, Thr or Val provided that if it is Ala, then one of the residues at -1 or 6 is a small residue;
 - (i) if the 3' base in the triplet is G, then position -1 is Arg;
 - (j) if the 3' base in the triplet is A, then position -1 is Gln and position 2 is Ala;
 - (k) if the 3' base in the triplet is T, then position -1 is Asn or position -1 is Gln and position 2 is Ser;
 - (l) if the 3' base in the triplet is C, then position -1 is Asp and position 1 is Arg;
- and,

when the central residue of a target triplet is C, the use of Asp at position 3 allows preferential binding to C over 5-meC; and,
wherein “++” residues are residues present in a C-terminal adjacent zinc finger, and when there is no C-terminal adjacent zinc finger, “++” interactions do not operate.

29. (New) The plant host cell or transgenic plant of claim 26 wherein there is an N-terminal zinc finger having a leader peptide MAEEKP added thereto.

30. (New) The plant host cell or transgenic plant of claim 25 wherein one or more of the zinc fingers of the polypeptide comprises a mutated model zinc finger domain.

31. (New) The plant host cell or transgenic plant of claim 30 wherein the model zinc finger domain is a zinc finger from a protein selected from the group consisting of Zif268, GLI, Tramtrack, or YY1.

32. (New) The plant host cell or transgenic plant of claim 25 wherein the zinc finger polypeptide has more than three zinc fingers.

33. (New) The plant host cell or transgenic plant of claim 32 wherein the zinc finger polypeptide has four, five, six, seven, eight or nine zinc fingers.

34. (New) The plant host cell or transgenic plant of claim 33 wherein the zinc finger polypeptide comprises zinc fingers 1-3 of TFIIIA, and three zinc fingers from Zif268, joined by zinc finger 4, including flanking sequences, of TFIIIA, acting as a linker.

35. (New) The plant host cell or transgenic plant of claim 24, wherein the target DNA

PATENT
USSN 09/732,348
674538-2001

sequence is operably linked to a coding sequence.

36. (New) The plant host cell or transgenic plant of claim 35, wherein transcription of the coding sequence is regulated by binding of the zinc finger polypeptide to the target DNA sequence.

37. (New) The plant host cell or transgenic plant of claim 24, wherein the target DNA sequence is part of an endogenous sequence.

38. (New) The plant host cell or transgenic plant of claim 24, wherein the target DNA sequence and coding sequence are heterologous to the cell.

39. (New) The plant host cell or transgenic plant of claim 24, wherein the zinc finger polypeptide is fused to a transcriptional activator domain.

40. (New) The plant host cell or transgenic plant of claim 34, wherein the zinc finger polypeptide is fused to a transcriptional activator domain.

41. (New) The plant host cell or transgenic plant of claim 40 wherein the transcriptional activator domain comprises VP16 transcriptional activator domain.

42. (New) The plant host cell or transgenic plant of claim 40 wherein the transcriptional activator domain comprises VP64 transcriptional activator domain.

43. (New) The transgenic plant host cell or transgenic plant of claim 25, wherein the zinc finger polypeptide is fused to a transcriptional repressor domain.

44. (New) The plant host cell or transgenic plant of claim 35, wherein the target DNA sequence is operably linked to a coding sequence.

45. (New) The plant host cell or transgenic plant of claim 40, wherein the target DNA sequence is operably linked to a coding sequence.

46. (New) The plant host cell or transgenic plant of claim 45 wherein the transcriptional activator domain comprises VP16 transcriptional activator domain.

47. (New) The plant host cell or transgenic plant of claim 45 wherein the transcriptional activator domain comprises VP64 transcriptional activator domain.

48. (New) The plant host cell of claim 25, wherein the zinc finger polypeptide is fused to a biological effector domain.


49. (New) The plant host cell or transgenic plant of claim 24 which is a transgenic plant.

PATENT
 USSN 09/732,348
 674538-2001

50. (New) The plant host cell or transgenic plant of claim 24 which is a plant host cell.


51. (New) A method of regulating transcription in a plant cell from a DNA sequence comprising a target DNA operably linked to a coding sequence, which method comprises introducing an engineered zinc finger polypeptide into said plant cell which polypeptide binds to the target DNA and modulates transcription of the coding sequence.

52. (New) The method of claim 51, wherein the zinc finger polypeptide has two or more zinc fingers and the zinc fingers have structures of the formula



wherein X is any amino acid and the numbers in subscript indicate possible numbers of residues represented by X.

53. (New) The method of claim 52 wherein the zinc finger structures have a binding motif represented by:



wherein each of X, X^a, X^b, X^c is any amino acid, the numbers in subscript indicate possible numbers of residues, and X X X X L X X H X X between X^c and X^b are designated positions -1, 1, 2, 3, 4, 5, 6, 7, 8, and 9.

54. (New) The method of claim 53 wherein X^a is E, K, T, S, Q, V, A or P, X^b is T or I, X^c is S or T, X₂₋₄ is two amino acids, with the first of which being S, E, K, T, P, or R, and the second amino acid being E, and the linker is T-G-E-K or T-G-E-K-P, and position 9 is Arg or Lys, and positions 1, 5, and 8 are hydrophobic amino acids and not Phe, Trp or Tyr.

55. (New) The method of claim 53 wherein one or more of the zinc fingers binds to a target DNA triplet in accordance with the following:

(a) if the 5' base in the triplet is G, then position 6 is Arg or position ++2 is Asp or position 6 is Arg and position 2 is Asp;

(b) if the 5' base in the triplet is A, then position 6 is Gln or Glu and ++2 is not Asp;

(c) if the 5' base in the triplet is T, then position 6 in is Ser or Thr and position ++2 is Asp or position 6 is a hydrophobic amino acid other than Ala;

(d) if the 5' base in the triplet is C, then position 6 in may be any amino acid, provided that position ++2 is not Asp;

PATENT
USSN 09/732,348
674538-2001

- (e) if the central base in the triplet is G, then position 3 is His;
 - (f) if the central base in the triplet is A, then position 3 is Asn;
 - (g) if the central base in the triplet is T, then position 3 is Ala, Ser, Ile, Leu, Thr or Val provided that if it is Ala, then one of the residues at -1 or 6 is a small residue;
 - (h) if the central base in the triplet is 5-meC, then position 3 is Ala, Ser, Ile, Leu, Thr or Val provided that if it is Ala, then one of the residues at -1 or 6 is a small residue;
 - (i) if the 3' base in the triplet is G, then position -1 is Arg;
 - (j) if the 3' base in the triplet is A, then position -1 is Gln and position 2 is Ala;
 - (k) if the 3' base in the triplet is T, then position -1 is Asn or position -1 is Gln and position 2 is Ser;
 - (l) if the 3' base in the triplet is C, then position -1 is Asp and position 1 is Arg;
- and,

when the central residue of a target triplet is C, the use of Asp at position 3 allows preferential binding to C over 5-meC; and,
wherein “++” residues are residues present in a C-terminal adjacent zinc finger, and when there is no C-terminal adjacent zinc finger, “++” interactions do not operate.

56. (New) The method of claim 53 wherein there is an N-terminal zinc finger having a leader peptide MAEEKP added thereto.

57. (New) The method of claim 52 wherein one or more of the zinc fingers of the polypeptide comprises a mutated model zinc finger domain.

58. (New) The method of claim 57 wherein the model zinc finger domain is a zinc finger from a protein selected from the group consisting of Zif268, GLI, Tramtrack, or YY1.

59. (New) The method of claim 52 wherein the zinc finger polypeptide has more than three zinc fingers.

60. (New) The method of claim 59 wherein the zinc finger polypeptide has four, five, six, seven, eight or nine zinc fingers.

61. (New) The method of claim 60 wherein the zinc finger polypeptide comprises zinc fingers 1-3 of TFIIIA, and three zinc fingers from Zif268, joined by zinc finger 4, including flanking sequences, of TFIIIA, acting as a linker.

62. (New) The method of claim 61, wherein the zinc finger polypeptide is fused to a

PATENT
USSN 09/732,348
674538-2001

transcriptional activator domain.

63. (New) The method of claim 62 wherein the transcriptional activator domain comprises VP16 transcriptional activator domain.

64. (New) The method of claim 62 wherein the transcriptional activator domain comprises VP64 transcriptional activator domain.

65. (New) The method according to claim 51 wherein the target DNA is part of an endogenous genomic sequence.

66. (New) The method according to claim 51 wherein the target DNA and coding sequence are heterologous to the cell.

67. (New) The method according to claim 51 wherein the zinc finger polypeptide is fused to a biological effector domain.

68. (New) The method according to claim 67 wherein the zinc finger polypeptide is fused to a transcriptional activator domain.

69. (New) The method according to claim 67 wherein the zinc finger polypeptide is fused to a transcriptional repressor domain.

70. (New) The method according to claim 51 wherein the plant cell is part of a plant and the target sequence is part of a regulatory sequence to which the nucleotide sequence of interest is operably linked.



Arabidopsis, Madison 1997 -- Information

8th International Meeting on Arabidopsis Research
June 25-29, 1997
Madison, Wisconsin USA

List of Abstracts, by presenting author

Search Abstracts, using any word or phrase

3-58 - Putterill, Joanna : The *CONSTANS LIKE 1 (COL1)* gene of *Arabidopsis* is circadian regulated ar... Page 1 of 1

3-58

The *CONSTANS LIKE 1 (COL1)* gene of *Arabidopsis* is circadian regulated and *COL1* transgenes influence flowering in transgenic plants.

Joanna Putterill (1), Susan Ledger (2), George Coupland (3), Carl Strayer (4)

(1) Plant Sciences Group, School of Biological Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand; (2) Plant Sciences Group, School of Biological Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand; (3) John Innes Institute, Colney, Norwich, UK; (4) Scripps Research Institute, La Jolla, San Diego, U.S.A [presenter's e-mail: j.putterill@auckland.ac.nz]

The *CONSTANS (CO)* gene promotes flowering in *Arabidopsis* and encodes a putative zinc finger transcription factor. Several *CO*-like genes exist in *Arabidopsis*. One of these genes, *COL1* is 67% identical to the *CO* protein at the predicted amino acid level and has a domain containing two zinc finger motifs (C-X₂-C-X₁₆-C-X₂-C) in the amino terminal region that is 86% identical to the zinc finger region of *CO*. *CO* and *COL1* appear to have arisen as a result of a tandem duplication event as they are separated by 3600 bases on chromosome 5 and are orientated in the same direction. The two genes show differences in their regulation and function. The *CO* transcript is rare, but expressed at higher levels in long day photoperiods (18 h light; 6 h dark) than in short days (10 h light; 14 h dark). Unlike *CO*, The *COL1* transcript is much more abundant in both photoperiods. However, *COL1* steady state transcript levels do cycle through the light/dark phases of a day and continue to fluctuate in plants shifted to continuous light. This indicates that *COL1* expression is under circadian control. The function of *COL1* in the development and flowering of *Arabidopsis* is being studied by generating plants in which *COL1* is either over expressed or reduced. Delayed flowering is seen in two antisense *COL1* transformants in all photoperiods tested. *COL1* over expressors flower slightly more rapidly than wild type. The effect of *COL1* on flowering therefore differs from that of the *CO* gene. How *COL1* influences flowering at the molecular level is unknown, but preliminary results indicate that *COL1* transgene expression may affect aspects of circadian regulation in plants.

The Plant Journal (2001) 28(6), 619–631

Functional importance of conserved domains in the flowering-time gene *CONSTANS* demonstrated by analysis of mutant alleles and transgenic plants

Frances Robson^{1,†}, M. Manuela R. Costa¹, Shelley R. Hepworth¹, Igor Vizir¹, Manuel Piñeiro¹, Paul H. Reeves¹, Joanna Putterill^{1,†}, and George Coupland^{1,2,*}

¹John Innes Centre, Colney Lane, Norwich NR4 7UH, UK and, ²Max-Planck-Institut für Züchtungsforschung, Carl-von-Linné-Weg 10, D-50829 Köln, Germany

Received 11 July 2000; accepted 6 August 2001.

*For correspondence (fax +49 2215062207; e-mail coupland@mplz-koeln.mpg.de).

[†]Present address: School of Biological Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand.

Summary

CONSTANS promotes flowering of *Arabidopsis* in response to long-day conditions. We show that *CONSTANS* is a member of an *Arabidopsis* gene family that comprises 16 other members. The CO-Like proteins encoded by these genes contain two segments of homology: a zinc finger containing region near their amino terminus and a CCT (CO, CO-Like, TOC1) domain near their carboxy terminus. Analysis of seven classical *co* mutant alleles demonstrated that the mutations all occur within either the zinc finger region or the CCT domain, confirming that the two regions of homology are important for CO function. The zinc fingers are most similar to those of B-boxes, which act as protein–protein interaction domains in several transcription factors described in animals. Segments of CO protein containing the CCT domain localize GFP to the nucleus, but one mutation that affects the CCT domain delays flowering without affecting the nuclear localization function, suggesting that this domain has additional functions. All eight *co* alleles, including one recovered by pollen irradiation in which DNA encoding both B-boxes is deleted, are shown to be semidominant. This dominance appears to be largely due to a reduction in CO dosage in the heterozygous plants. However, some alleles may also actively delay flowering, because overexpression from the CaMV 35S promoter of the *co-3* allele, that has a mutation in the second B-box, delayed flowering of wild-type plants. The significance of these observations for the role of CO in the control of flowering time is discussed.

Keywords: *Arabidopsis*, flowering, photoperiod, B-box zinc finger.

Introduction

The *CONSTANS* (CO) gene was originally identified because of the late-flowering phenotype of *co* mutant plants (Koornneef *et al.*, 1991; Redei, 1962). The phenotype of the mutant suggested that CO protein promotes the transition from vegetative growth to flowering, and this was supported by the demonstration that plants carrying extra copies of CO (Putterill *et al.*, 1995) or overexpressing CO from the 35S promoter (Onouchi *et al.*, 2000) flowered earlier than wild-type. The CO gene was cloned (Putterill *et al.*, 1995), and the predicted protein product contains two regions of 43 amino acids towards the amino terminus of the protein that are closely related in sequence. Each of these regions contains an arrangement of cysteine

residues similar to that present in the zinc fingers of GATA transcription factors, but little direct homology to these proteins was detected (Putterill *et al.*, 1995). The construction of a translational fusion of CO to the ligand binding domain of the rat glucocorticoid receptor (CO:GR; Simon *et al.*, 1996) provided further evidence that CO acts to influence transcription. Introduction of CO:GR into *co* mutant plants did not correct the mutant phenotype until the plants were treated with the steroid dexamethasone (dex). A similar fusion of the plant transcription factor LEAFY to the GR domain was retained in the cytoplasm until dex was added, suggesting that the GR domain operates in plants as it does in animals by sequestering the

620 Frances Robson et al.

fusion protein in the cytoplasm (Wagner *et al.*, 1999). Furthermore, induction of CO:GR with dex is associated with the rapid transcription of likely target genes, such as *SOC1* that encodes a MADS box transcription factor (Samach *et al.*, 2000). Taken together these data support the idea that CO acts in the nucleus to promote flowering by altering the transcription of downstream target genes.

Despite the considerable genetic and molecular data available on genes that interact with CO to regulate flowering (Kardailsky *et al.*, 1999; Kobayashi *et al.*, 1999; Onouchi *et al.*, 2000; Samach *et al.*, 2000; Soppe *et al.*, 2000), little is known of the function of the CO protein nor of the roles of the different domains of the protein. Here several molecular-genetic approaches are used to address the function of CO. The availability of the genomic sequence of *Arabidopsis* (Arabidopsis Genome Initiative, 2000) allowed us to identify an extensive family of related proteins and thereby to recognize domains conserved between these proteins that may be functionally important. The functional significance of these homologies is addressed by analysing the sequence of eight mutant alleles and determining the positions of the mutations within the CO protein.

The blocks of homology identified in the sequence comparisons and the positions of the mutations suggest that CO protein has a modular structure with two zinc fingers near the amino terminus and a domain of unknown function near the C-terminus. Transcription factors frequently have a modular structure in which for example the DNA-binding domain is separable from the transcriptional activation or repression domains (Hope and Struhl, 1986; Keegan *et al.*, 1986). Mutant proteins in which one domain is inactivated but the other is intact can act as dominant negative forms that repress the function of the wild-type protein and this has been used to investigate the function of plant transcription factors (e.g. Mizukami and Ma, 1997; Unger *et al.*, 1993). This approach was used to address the

function of CO by making transgenic wild-type plants overexpressing mutant proteins in which one or other of the protein domains are affected.

The intracellular location of plant proteins can be determined by constructing translational fusions with green fluorescent protein (GFP; Haseloff *et al.*, 1997; Grebenok *et al.*, 1997). This approach was also used to determine whether CO is present in the nucleus, and whether mutations that affect one of the protein domains prevent nuclear localization.

The results of these approaches are used to propose models of how CO acts to regulate flowering time.

Results

CONSTANS contains two B-boxes that are altered in five mutant alleles

Analysis of the CO protein using the SMART program (Schultz *et al.*, 1998, 2000) identified strong similarity between the proposed zinc fingers of CO and those of the B-box (Figure 1a and b). The B-box is a class of zinc finger, usually of the type C-X²-H-X²-C-X²-C-X²-H-X²-H, that was identified in a variety of animal proteins including several transcription factors (XNF7, RPT-1, EFP), ribonucleoproteins (SS-A/Ro, PwA33) and proto-oncogene products (RFP, PML, TIF1) (reviewed in Borden, 1998; Reddy *et al.*, 1992). The CO protein contains two B-box motifs that show 46% identity and 86% similarity with each other (Figure 1c). There are seven conserved residues that could act as metal-binding residues within the B-box motif, and all of these are conserved in both CO B-boxes (Figure 1b). Four of these residues were shown to bind zinc in the B-box structure of the *Xenopus* protein XNF-7 (Borden *et al.*, 1995), and these four residues are conserved in both of the CO B-boxes (Figure 1b).

Figure 1. Comparison of CO with CO-like proteins and with B-box containing proteins of animals.

(a) Comparison of the B-boxes of CO with several B-box proteins of animals. The animal B-box proteins are XNF7 (Miller *et al.*, 1989), PwA33 (Bellini *et al.*, 1993), RPT-1 (Patarca *et al.*, 1988), SS-A/Ro (Chan *et al.*, 1991), RFP (Takahashi *et al.*, 1988), ATDC (Leonhardt *et al.*, 1994), EFP (Inoue *et al.*, 1993), TIF1 (Miki *et al.*, 1991) and PML (Goddard *et al.*, 1991). B1 and B2 are the most N-terminal or C-terminal B-box, respectively. (b) The consensus spacing of C and H residues in animal B-box proteins compared with the spacing between these residues in the CO B-boxes. X represents any amino acid. The asterisks indicate those residues predicted to bind zinc in the NMR structure of the XNF7 B-box (Borden *et al.*, 1995). (c) Alignment of the first and second B-boxes of CO with those of the CO-like proteins. The predicted amino acid substitutions in *co-2*, *co-3*, *co-4* and *co-6*, as well as the predicted deletion in *co-1* are indicated. Accession numbers are CO (emb1 X94937; At5g15840; Putterill *et al.*, 1995), COL1(emb1 Y1005; At5g15850; Putterill *et al.*, 1997), COL2(gb L81120; At3g02380; Ledger *et al.*, 1996), COL3(gb AC066585; At2g24790), COL4(gb AF069716; At5g24930), COL5(dgb AB018118; At5g57660), COL6(gb AC011915; At1g68520), COL7(gb AC016682; At1g73870), COL8(gb AC016041; At1g49130), COL9(gb AC009176; At3g07850), COL10(dgb AB023039; At5g48520), COL11(emb Z97338; At4g15250), COL12(dgb AP000739; At3g21880), COL13(gb AC005309; At2g47890), COL14(gb AC002332; At2g33500), COL15(gbAC069471; At1g28050) and COL16(gbAC079281; At1g25440). (d) Schematic representation of the sequence motifs found within the CO and COL proteins, or within the animal B-box proteins. The CO and COL proteins contain one or two B-boxes near their N-terminus, and a C-terminal domain recently named the CCT domain (Strayer *et al.*, 2000). The second B-box of COL9, 10, 11, 12, 13, 14 and 15 is relatively dissimilar to that of CO and is shown as an open rectangle. Moreover, the second B-boxes of COL9, COL10, COL11, and COL12 do not exactly match the B-box consensus and therefore may not be active B-box domains. The animal proteins carry the illustrated arrangement of RING fingers, B-boxes and coiled-coil domains. (e) Alignment of the carboxy-terminal CCT domains of CO and COL1-16. The predicted amino acid substitutions in *co-5* and *co-7* are illustrated.

(b) CONSTANS B-box

B-box consensus
(Barden 1998)

C X₂ C X₈ C X₇ C X₂ C X₄ H X₈ H

C X₂ H X₇₋₁₀ C X₇ C X₂ H X₃₋₅ H X₂₋₆ H


* *

[illegible]

```

CONSTANS B2
COL1 B2
COL2 B2
COL3 B2
COL4 B2
COL5 B2
COL6 B2
COL7 B2
COL8 B2
COL9 B2
COL10 B2
COL11 B2
COL12 B2
COL13 B2
COL14 B2
COL15 B2
consensus

```



(e)

CONSTANS CCT

COL1 CCT

COL2 CCT

COL3 CCT

COL4 CCT

COL5 CCT

COL6 CCT

COL7 CCT

COL8 CCT

COL9 CCT

COL10 CCT

COL11 CCT

COL12 CCT

C L13 CCT

COL14 CCT

COL15 CCT

COL16 CCT

consensus

ReervLYRERK EKR LLEKKA AS RQVAKPR

Two *CO-LIKE* (*COL*) genes were previously described in *Arabidopsis* (Figure 1c; Ledger *et al.*, 1996, 2001; Putterill *et al.*, 1997). A BLAST search of the *Arabidopsis* genome sequence was performed to determine whether there were other members of this gene family. By analysing the *Arabidopsis* genome sequence (Arabidopsis Genome Initiative, 2000) a total of 16 *COL* genes were identified that contained one or two B-boxes at the amino terminus of the predicted protein (Figure 1c), and another highly conserved domain at the carboxy terminus (see below). Five *COL* proteins have two B-box motifs closely related to those of CO, seven contain a second B-box less closely related to those of CO and four have only one B box motif.

The *CO* gene was amplified by PCR from each of the seven mutants and the resulting fragments sequenced to identify the mutations. Five of the seven *co* alleles contain mutations that affect residues in the B-boxes (Figure 1c), suggesting that these are important for CO protein function. The *co-6* mutation causes substitution of an alanine for a valine in the first B-box. The *co-2* mutation converts an arginine to a histidine towards the carboxy-terminal end of the first B-box. The *co-1*, *co-3* and *co-4* mutations affect the second B-box. The *co-3* mutation affects a histidine residue that, based on the analysis of the XNF-7 B-box structure, is likely to be required for zinc binding (Figure 1a, b and c; Borden *et al.*, 1995).

CONSTANS contains a carboxy-terminal domain that is conserved among related proteins and is functionally important

The two remaining mutant alleles, *co-5* and *co-7*, do not affect the B-box structures. These mutations affect adjacent proline and arginine residues in a highly conserved basic domain of approximately 43 amino acids near the C-terminus of the protein (Figure 1e). This novel domain was previously proposed to contain a nuclear localization sequence (Robert *et al.*, 1998), and is also found in all 16 *COL* proteins (Figure 1e). Homology to this domain was also recently described in proteins that do not contain B boxes (Kurup *et al.*, 2000; Makino *et al.*, 2000; Strayer *et al.*, 2000).

The carboxy-terminal domain of *CONSTANS* is sufficient to localize GFP to the nucleus, but the *co-7* allele does not affect nuclear localization

To test whether CO protein is localized to the nucleus, and whether this is conferred by the carboxy-terminal domain translational fusions were constructed between GFP and CO or CO derivatives.

A translational fusion of GFP and CO (GFP:CO) was constructed in plasmid pAVA121 (von Arnim *et al.*, 1998; Experimental procedures). GFP was fused to the N-ter-


minus of the CO protein and expressed from a double 35S promoter (Experimental procedures). A transient expression assay in onion bulb epidermal cells was used to assess the cellular location of the fusion protein. Cells bombarded with the control plasmid pAVA121 showed GFP localization both in the cytoplasm and in the nucleus (Figure 2a), as previously shown (Grabenok *et al.*, 1997; Haseloff *et al.*, 1997). However, GFP:CO fusion protein was located in the nucleus and was not detected in the cytoplasm (Figure 2b). CO can therefore localize GFP to the nucleus of these cells, suggesting that CO is a nuclear protein. To confirm that GFP:CO retained biological activity, the 35S::GFP:CO fusion was introduced into *co-2* mutants. The transgenic plants were early flowering and showed a similar phenotype to 35S::CO (Onouchi *et al.*, 2000). The cellular location of the fusion protein was analysed in root, hypocotyl and cotyledon cells and shown to be located in the nucleus (Figure 2g, h and i).

To determine whether the conserved domain at the C-terminus of the CO protein is responsible for nuclear localization, a series of CO deletion derivatives were fused to GFP. The plasmid containing GFP fused to the region of CO between amino acids 304 and the C-terminal amino acid 373 (GFP:CtermCO; Experimental procedures) was bombarded into onion cells. The GFP:CtermCO fusion protein was observed only in the nucleus (Figure 2c), suggesting that this C-terminal sequence is sufficient to target GFP to the nucleus. Some proteins contain multiple NLSs (Varagona *et al.*, 1992), and therefore to test whether another NLS was present in the N-terminal portion of CO, a truncated CO-protein lacking the C-terminal residues 302–373 was produced (GFP:NtermCO). This fusion protein was tested for intracellular localization as described earlier. Fluorescence was observed both in the cytoplasm and nucleus (Figure 2d), demonstrating that this portion of CO does not localize GFP exclusively to the nucleus. Taken together these experiments suggest that the only region of CO containing an NLS is between amino acids 304 and 373.

The mutant alleles *co-5* and *co-7* contain mutations in the C-terminal region of the protein that was demonstrated above to be sufficient for nuclear localization. The C-terminal regions (between amino acids 304 and 373) from these mutant proteins were fused to GFP to determine whether the mutations affected nuclear localization of the protein. Cells bombarded with 35S::GFP:*co-5* DNA showed GFP localization in the cytoplasm and in the nucleus (Figure 2e), suggesting that the *co-5* mutation affects the subcellular localization of the CO protein. The distribution of GFP:*co-5* was similar to that of the GFP control but the level of expression was lower. However, GFP:*co-7* showed GFP localization only in the nucleus (Figure 2f), suggesting that this mutation does not affect nuclear import of the CO protein.

Figure 2. Subcellular localization of CO:GFP fusion protein.

(a)–(f) Images of onion epidermal cells stained with DAPI. In each case the tissue was viewed using epifluorescence optics with blue excitation to detect GFP (left) and UV-excitation to detect nuclei. Cells bombarded with 35S::GFP. Bars = 100 μ m. (a) Cells bombarded with 35S::GFP. (b) Cells bombarded with 35S::GFP:CO. (c) Cells bombarded with GFP:CtermCO. (d) Cells bombarded with GFP:NtermCO. (e) Cells bombarded with GFP:co-5. (f) Cells bombarded with GFP:co-7. All samples were stained with DAPI and viewed under epifluorescence optics with blue (left) and UV (right) excitation. (g)–(i) Images of 11-day-old-transgenic *Arabidopsis* plants carrying 35S::CO:GFP. (g) Junction of hypocotyl and root. Merged images of green and red channels. GFP fluorescence detected in the green channel and chlorophyll autofluorescence in the red channel. (h) Hypocotyl tissue. Merged images of green and red channels as for G. (i) Root hairs.



Isolation and characterization of co-8, a likely null allele

Based on their sequences none of the seven classical *co* mutant alleles were predicted to certainly abolish CO function. All seven caused in-frame changes, including *co-7* which was induced with X-rays. This raised the possibil-

ity that complete loss of function may generate pleiotropic effects, and that the seven classical alleles were all hypomorphs identified by screening phenotypically for late-flowering plants. Therefore, pollen irradiation was used to identify loss-of function alleles without making the assumption that these would only cause late flowering. An

appropriate population of plants made with γ -irradiated pollen was described previously (Vizir *et al.*, 1994). Pollen from Landsberg *erecta* plants was irradiated and used to cross-fertilize plants homozygous for the genetically linked mutations *lu co-1 ms1 ttg*. Twenty-six late-flowering M1 plants were identified, and these potentially carried novel *co* mutant alleles derived from irradiation. These plants were self-fertilized, and six of them gave rise to M2 progeny that were all late flowering, although only one of these lines was fertile. The mutation in this late-flowering line was preliminarily called *co-8*, and was tested further at the genetic and molecular levels.

Southern analysis of *co-8* using probes derived from the *CO* genomic region demonstrated that a deletion had removed 1.3 kb from the 5' end of the *CO* gene. The deletion included the sequence encoding the two B-boxes and approximately 1 kb of the 5' non-coding region (Figure 3a). However, the pattern of hybridizing fragments detected in the Southern analysis could not be explained by a simple deletion. For example, probes that flanked the deletion on either side did not hybridize to the same *Eco*RI or *Hind*III fragments, although they would have been predicted to do so had a simple deletion occurred. This suggested that an insertion or an inversion had probably occurred at the deletion breakpoints.

To analyse the structure of *co-8* more carefully both junctions between *CO* and the presumed rearrangement were isolated by using Inverse Polymerase Chain Reaction (IPCR) and by constructing a cosmid library from DNA extracted from *co-8* mutants (Robson, 1998; Experimental procedures). The exact locations of the breakpoints were defined by DNA sequencing using primers (co52 and co17 in Experimental procedures; Figure 3a) designed to the *CO* gene to sequence into the rearrangement on either side. This identified the breakpoints within *CO* to be 1025 bp upstream of the ATG and 304 bp downstream of the ATG. Adjacent to the breakpoints at both ends of the rearrangement was novel DNA not associated with the *CO* gene in wild-type plants. Both of these unknown sequences were used in a BLAST search against the database and both were identical to sequences within P1 clone MPI10 that contains DNA from *Arabidopsis* chromosome 5. The two junction sequences however, are not directly adjacent in the sequence of MPI10 but 1208 bp apart. On the wild-type chromosome, the *CO* gene (on BACF14F8) is approximately 17 Mb from the DNA within clone MPI10 according to the physical maps of chromosome 5 (TAIR). The *co-8* allele was probably therefore derived from an irradiation-induced event in which two deletions occurred approximately 17 Mb apart. One of these was within the *CO* gene, and the other within the DNA cloned in BAC MPI10. These deletions were then repaired such that the intervening 17 Mb segment of chromosome 5 was inverted (Figure 3a).




Figure 3. Structure of the *co-8* allele.

(a) Proposed derivation and final structure of the *co-8* allele. The first diagram illustrates the structure of the wild-type chromosome. The *CO* gene is illustrated as a rectangle containing the B-boxes (marked with internal horizontal lines) and the CCT domain (marked with internal vertical lines). DNA within BAC MPI10 is marked with black squares. *CO* and MPI10 are approximately 17 Mb apart, and the orientation of this intervening DNA is denoted by arrowheads. The positions of primers used to analyse the structure of the mutant allele are illustrated, their use is described in the text and their sequences appear in the Experimental procedures. The second diagram shows the location of two deletions that are proposed to have occurred in the generation of the *co-8* allele, and their positions relative to the primer sequences. The third diagram illustrates the proposed final structure of the allele. The intervening DNA is inverted such that the MPI10 sequence containing co75 is adjacent to *CO* sequence containing co17 and MPI10 sequence containing co74 is adjacent to MPI10 sequence containing co74. (b) Analysis of *CO* RNA present in *co-8* mutants by RT-PCR. Experiment I was performed using primers oli5 and co50 (Experimental procedures). These detected the 3' end of the wild-type *CO* mRNA extending from the single intron over the region encoding the CCT domain. Experiment II was performed using primers oli9 and co53 (Experimental procedures). These detected the 5' end of the wild-type *CO* mRNA extending from the single intron to the position at which co53 anneals within the first exon, as shown in the diagram. Experiment III shows the detection of the *APETALA2* mRNA as a control for the abundance of cDNA used in each of the previous RT-PCR experiments.

In the *co-8* allele 1025 bp of the 5' untranslated region is deleted and the truncated *CO* ORF is fused to DNA from BAC MPI10 that is not normally associated with the *CO* gene. Reverse transcriptase-PCR was used to test whether

Analysis of *CONSTANS* 625

CO mRNA was present in *co-8* plants (Figure 3b). No transcript was amplified from cDNA made from *co-8* mutants when one of the primers (*co53*) used for the PCR was designed to anneal to DNA removed by the deletion in *co-8*, although cDNA made from wild-type plants produced a transcript of the expected size. However, PCR primers (*co50* and *oli5*) that annealed to part of the CO ORF that is retained in *co-8*, amplified a product of the expected size from cDNA made from both *co-8* mutants and wild-type plants. Therefore, the remaining portion of the CO ORF is still transcribed in the *co-8* rearrangement.

Although a novel transcript is detected in the *co-8* mutant, the deletion of both B-boxes suggests that the mutant will lack any CO activity.

All eight *constans* alleles are semidominant

The *co-2*, *co-3* and *co-4* alleles were previously reported to be semidominant (Koorneef *et al.*, 1991). Based on the phenotype of homozygous *co-2* mutant plants carrying transgenic copies of the wild-type gene, Putterill *et al.* (1995) proposed that the semidominance of *co-2* was due to haploinsufficiency rather than to *co-2* encoding an altered product that delayed flowering.

To determine whether all seven classical alleles and the new *co-8* allele all cause semidominance, they were each independently crossed to Landsberg *erecta*. The F1 progeny were sown in long-day conditions and their flowering time compared to that of wild type and homozygous mutant controls. All of the F1 plants showed an intermediate flowering time phenotype (Table 1), indicating that all eight alleles are semidominant. This was confirmed in the F2 generation, in which approximately 50% of plants showed intermediate flowering times (data not shown).

Transgenic wild-type plants over-expressing the *co-3* protein are late flowering

The CO gene contains two functional domains based on homology searches and analysis of mutant alleles. Both of these domains may facilitate interactions between CO and other proteins (see Discussion). This suggested that mutant forms of CO in which one domain is altered but the other is intact might sequester interacting proteins into inactive complexes, and thereby lead to a late-flowering phenotype. Such a dominant negative function has been proposed recently to explain the effect of mutant forms of B-box proteins (Peng *et al.*, 2000). To test the effectiveness of this approach, the *co-3* allele, that carries a mutation in the second B-box of CO, and the *co-7* allele, that carries a mutation in the carboxy-terminal domain, were each expressed from the CaMV 35S promoter (Experimental procedures). These transgenes were then introduced into wild-type Landsberg *erecta* plants.

Table 1. Flowering time of wild type and the *constans* homozygous and heterozygous mutants, measured as the total number of leaves produced before the onset of flowering. Data from 20 individuals for each genotype \pm SE

Genotype	Homozygote (leaf number)	Heterozygote (leaf number)	Mutagen
WT	7.5 \pm 0.2	—	—
<i>co-4</i>	11.3 \pm 0.4	9.8 \pm 0.2	EMS
<i>co-5</i>	14.4 \pm 0.4	11.5 \pm 0.4	EMS
<i>co-2</i>	19.4 \pm 0.9	13.3 \pm 0.3	EMS
<i>co-8</i>	22.5 \pm 0.3	16.2 \pm 0.7	γ - ray
<i>co-6</i>	23.7 \pm 0.5	11.9 \pm 0.3	EMS
<i>co-1</i>	25.6 \pm 0.6	13.5 \pm 0.3	X - ray
<i>co-7</i>	28.5 \pm 0.8	10.2 \pm 0.2	EMS
<i>co-3</i>	29.1 \pm 1.2	15.2 \pm 0.6	EMS

Approximately 150 kanamycin-resistant T1 plants were identified after infiltration of Landsberg *erecta* plants with *Agrobacterium* cells carrying the 35S::*co-3* construct. Around 20 of these T1 plants appeared to flower at least slightly later than wild-type plants. The T1 plants were self-fertilized and individuals homozygous for the T-DNA were identified in five of the late-flowering lines. T3 progeny of these five lines were then scored for flowering time under long-day conditions (Figure 4). All five lines flowered significantly later than wild-type plants, although none were as late flowering as the *co-2* or *co-3* mutant. Northern blots demonstrated that *co-3* mRNA was over-expressed in the late-flowering 35S::*Co-3* lines, and therefore that the late-flowering phenotype was not due to cosuppression causing a reduction in expression of the *co-3* and CO mRNAs. This indicates that over-expression of the *co-3* allele, that carries a mutation in one of the B-boxes, can delay flowering of wild-type plants.

A similar experiment was performed with the 35S::*co-7* construct and a total of 29 kanamycin-resistant T1 plants were identified. However, none of these flowered later than wild-type plants. These were self-fertilized and in the T2 generation their flowering time was tested under long and short days. None of the transformants flowered late under long days, suggesting that the 35S::*co-7* construct did not generate a dominant negative phenotype. Some of the 35S::*co-7* transformants flowered earlier than wild-type under short days, indicating that the protein encoded by the *co-7* allele may retain some residual CO activity.


Discussion

CO is a member of a novel family of B-box containing proteins

The CO zinc finger regions are most similar to those of B-box proteins. The seven potential zinc-binding residues

626 Frances Robson et al.

(a)



(b)




Figure 4. The effects of overexpression of the *co-3* allele. (a) Flowering times of Landsberg *erecta*, *co-2*, *co-3* and *35S::CO* plants compared to the flowering times of five independent *35S::co-3* transformants. The total numbers of leaves formed prior to the onset of flowering are shown. Error bars represent the SE for 20 individuals for each genotype growing under long day conditions. (b) A schematic illustration of the *35S::CO* and *35S::co-3* constructs.

within the B-box consensus sequence are conserved in the CO and most of the COL B-boxes. Furthermore, the *co-3* allele, which causes the most severe delay in flowering time, alters a histidine in the second B-box that corresponds to a histidine shown to bind zinc in the solution structure of the B-box of the *Xenopus* protein XNF-7 (Borden *et al.*, 1995). Although the zinc fingers of CO were

originally compared with those of GATA transcription factors (Putterill *et al.*, 1995), based on the spacing of four of the cysteine residues within the CO fingers, the similarity to the more recently described B-boxes is much stronger. Putterill *et al.* also pointed out the lack of direct homology with GATA transcription factors (Putterill *et al.*, 1995).

The function of B-box proteins in plants has not previously been discussed. In animal proteins, the B-box domain is usually part of a tripartite motif comprising a zinc-binding RING finger and a B-box domain followed closely (5–8 amino acids) by a predicted α -helical coiled-coil domain (RBCC family; Figure 1). The spacing between the three elements is highly conserved suggesting that the relative position of the domains is of functional importance. Proteins in a subfamily of this group, defined by the gene for ataxia-telangiectasia group D (ATDC) (Leonhardt *et al.*, 1994), have one or two B-boxes and a coiled coil domain but no RING finger. Another variation in the arrangement of RBCC domains is found in the protein kinase C-interacting protein (RBCK1) which has two coiled coil domains followed by a RING finger, a B-box and a B-box-like domain. This is the only published example of a protein that does not contain the coiled-coil domain after the B-box motif (Tokunaga *et al.*, 1998).

CO and the other COL proteins are unusual in containing one or two B-box domains with no coiled-coil domain or RING finger. There are several plant proteins containing RING fingers (COP1, Deng *et al.*, 1992; A-RZF, Zou and Taylor, 1997; PRT1 Potuschak *et al.*, 1998) and in COP1 this is followed by a coiled-coil domain (Deng *et al.*, 1992). However none of these plant RING finger proteins contain B-boxes.

The RBCC motif is believed to mediate protein-protein interactions (Borden, 1998; El-Husseini *et al.*, 2000; Peng *et al.*, 2000; Tsuzuki *et al.*, 2000). However, the two B-boxes in CO may not function in a similar way to those in the RBCC motif. For example, the RBCC domain of the transcriptional corepressor KAP-1 appears to function as an integrated structural unit in which the RING finger, the B-box and the coiled-coil region are all required for interaction with the transcriptional repression module KRAB (Peng *et al.*, 2000). However, in other cases the B-boxes appear to function autonomously. For example, the transcription factor GATA-2 interacts specifically with the B-box region of promyelocytic leukaemia protein (Tsuzuki *et al.*, 2000).

The role of the conserved carboxy-terminal domain of CO

The carboxy-terminal region of CO was sufficient to direct GFP to the nucleus, suggesting that nuclear localization is one function of this region. Such a function for this region

was originally proposed based on the similarity of a portion of it to the consensus sequence for an NLS (Robert *et al.*, 1998). More recently, a related region in the TOC1 protein was shown to direct TOC1 to the nucleus in transient expression assays, and was termed the CCT (CO, COL, TOC1) domain (Kurup *et al.*, 2000; Makino *et al.*, 2000; Strayer *et al.*, 2000). Nevertheless the carboxy-terminal domain of TOC1 shows only 51% identity to that of CO whereas the least closely related COL protein, COL14, shows 60.5% identity. The experiments described here establish that the CCT domain in CO shares the nuclear localization function with the related domain in TOC1, and the early flowering of the 35S::CO:GFP plants confirmed that CO:GFP located in the nucleus retains biological activity.

However, in addition to nuclear localization, the CCT domain probably has other functions. This was originally suggested because the conserved region is 43 amino acids long, which is a longer stretch of contiguous homology than is shown by nuclear localization sequences (Raikhel, 1992). The demonstration that the *co-7* allele has a severe effect on flowering time but does not affect the nuclear localization function of this domain further suggests that the domain has an additional role in CO activity.

A CCT domain is present in at least 18 proteins, including TOC1, that do not contain B-boxes (Strayer *et al.*, 2000 and data not shown). There are also a further 13 proteins that contain one or two B-boxes but do not have the CCT domain. These include the salt-tolerance protein STO (Lippuner *et al.*, 1996). The existence of proteins containing only one of these domains, either B-box or CCT-domain, suggests that these domains act independently of one another. This is supported by the observation of Kurup *et al.* (2000) who showed that the CCT domains of CO and TOC1 (also called ABI3 Interacting Protein 1) interact in yeast cells with the *Arabidopsis* transcription factor ABI3. This interaction was reduced approximately two-fold by both the *co-5* and *co-7* mutations. Therefore, the carboxy-terminal region probably has a role in protein-protein interaction as well as in nuclear localization.

The dominance of the co mutations

Three *co* mutant alleles were previously shown to be semidominant with the heterozygotes showing a phenotype intermediate between the homozygous mutants and wild-type (Koornneef *et al.*, 1991; Redei, 1962). Putterill *et al.* (1995) proposed that this was likely to be caused by haploinsufficiency, in which the heterozygotes did not produce enough CO protein to promote early flowering, rather than the mutant allele encoding an altered gain of function protein. This was proposed because transgenic mutants homozygous for the *co-2* allele and carrying wild-type CO as a transgene flowered as early as wild-type

plants. We have now shown that all eight mutant alleles are semidominant. The novel *co-8* allele, which we isolated, may be a null allele because the DNA encoding the translational start site and both B-boxes is deleted, although the remaining portion of the *co-8* mRNA may still be translated to produce a truncated protein. This truncated protein would carry the CCT domain (Figure 3) and may actively delay flowering, as was shown for overexpression in wild-type plants of the *co-3* allele, which also carries an intact CCT domain and impaired B-box domain. In contrast, overexpression in wild-type plants of the *co-7* allele, which encodes intact B-boxes and an impaired CCT domain, did not delay flowering, although this allele was semidominant when tested in heterozygous plants (Table 1). Therefore, the observation that *co-8* and *co-7* alleles are semidominant is consistent with the proposal that the dominance of *co* mutations is caused by haploinsufficiency.

Nevertheless, at least for some alleles the semidominance may be caused by a combination of haploinsufficiency and the mutant allele encoding an altered product that actively delays flowering. The late-flowering phenotype of Landsberg *erecta* plants carrying the 35S::*co-3* transgene clearly indicates that at least when overexpressed this allele can actively delay flowering. The *co-3* mutation affects a histidine residue that is predicted to be essential for zinc-binding within the second B-box. The active delay in flowering time caused by overexpression of this protein may be a consequence of the *co-3* protein sequestering wild-type CO protein or proteins required for CO function into inactive complexes. The sequestration may occur by proteins binding to the first B-box of *co-3* or to the CCT domain, neither of which is affected by the *co-3* mutation.

Implications for the roles of CO and CO-Like proteins in regulating flowering time

CO is a nuclear protein (Figure 2) that acts to promote flowering time by rapidly inducing the expression of downstream flowering-time genes such as *SOC1* and *FT* (Samach *et al.*, 2000). The zinc fingers of CO are required for CO function and are most similar to B-box motifs, which are predicted to mediate protein-protein interaction rather than DNA binding. This suggests that to activate transcription of downstream genes, CO may be recruited to promoters by DNA binding proteins. Such a role for B-box proteins has been described in animals. For example, the transcription factor GATA-2 recruits the B-box protein promyelocytic leukemia (PML) to DNA, and PML enhances the ability of GATA-2 to activate transcription (Tsuzuki *et al.*, 2000). Similarly, the Krüppel associated box (KRAB) that acts as a transcriptional repression module must interact with the RBCC protein KAP-1 in

order to cause gene silencing (Peng *et al.*, 2000). The KAP-1 protein is recruited to DNA by zinc-finger DNA binding proteins that carry the KRAB domain. These examples may describe a paradigm for CO function, and suggest that it may interact with specific DNA binding proteins that enable its recruitment to DNA. The observation that the carboxy-terminal regions of CO and TOC1 will interact with the DNA-binding protein ABI3 (Kurup *et al.*, 2000), suggests that ABI3 or transcription factors of the same class may be responsible for the recruitment of CO and COL proteins to DNA.

The evolution of the family of 16 COL proteins that contain the B-boxes and the carboxy-terminal domain was recently discussed (Lagercrantz and Axelsson, 2000), but their function is unknown. Overexpression of *COL1* shortened the period length of circadian clock regulation, but did not affect flowering time (Ledger *et al.*, 2001). In some cases the B-boxes are closely related in sequence to those of CO (Figure 1), however, so far there is no evidence that they regulate flowering time, and they may interact with transcription factors that do not associate with CO, and thereby regulate a different set of target genes. Closely related RBCC proteins were previously shown to interact with specific protein partners (Cainarca *et al.*, 1999).

Further understanding of the function of the CO and COL family is likely to come from identifying interacting proteins, some of which may recruit the B-box proteins to specific sets of target genes.

Experimental procedures

Plant material and growth conditions

Seeds from Landsberg *erecta* – Ler-0 (NW20), *tt4-1* (N85) and EMS mutants *co-2* (N175), *co-3* (N178), *co-4* (N177), *co-5* (N178), *co-6* (N179) and *co-7* (N180) were obtained from M. Koornneef. These mutants are all in a Landsberg *erecta* background. Seeds from Redei's X-ray mutant *co-1* (N3122) were also provided by M. Koornneef. This mutant is in Landsberg – La-0 (N1298). *co-1* is also available in Landsberg *erecta* – *co-1 er-1* (N3135). Seeds from γ -irradiated *lu-1 co-1 ms1-1 ttg-1* (N240) were provided by I. Vizir.

In the summer plants in the glasshouses were grown in natural daylight. In the winter supplementary light was provided so that the minimum day length was 18 h. Flowering time was measured under defined conditions by growing plants in Sanyo Gallenkamp as described by Putterill *et al.* (1995) and Robson (1998).

DNA and RNA extraction

Plant genomic DNA was extracted as described by Dean *et al.* (1992). To make the *co-8* cosmid library the DNA was further purified on a caesium chloride gradient prior to digestion (Sambrook *et al.*, 1989). RNA for analysis of *co-8* by RT-PCR was extracted as described by Putterill *et al.* (1995).

Cloning and sequencing of the *co* mutant alleles

DNA was extracted from seedlings as described above. A pair of primers designed to amplify the *CO* gene had previously been designed (Putterill *et al.*, 1995); *co41* (5'-GGTCCAACGAAGAAGTGC-3') and *co42* (5'-CAGGGAGGCGTGAAAGTGT-3'). These were used to amplify a 1.95-kb fragment from wild-type and *co* mutants *co-1* to *co-7*, in duplicate PCR reactions. The PCR products were blunt-ended using T4 DNA polymerase and cloned into the *Eco* RV site of pBluescript (SK +).

Library construction and screening

DNA from the *co-8* mutant was extracted and purified as described above. The library was constructed as described in Schaffer *et al.* (1998) by ligating plant DNA partially digested with *Sau* 3 A into the *Bam* HI site of cosmid vector c04541 (Jones *et al.*, 1992). The recombinant cosmids were packaged in Gigapack II Gold packaging extracts (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions and plated using *Escherichia coli* XL1 Blue MR.

Analysis of expression by RT-PCR

RNA was extracted from duplicate samples of tissue from 10-day-old seedlings as described above and cDNA prepared as described by Putterill *et al.* (1995). Primer pairs used were as follows: to amplify the 5' end of the *CO* transcript primers *co53* (5'-ACGCCATCAGCGAGTTCC-3') and *oli9* (5'-AAATGTATGCGTTATGGTTAATGG-3') were used. To amplify the 3' end of the *CO* transcript primers *co50* (5'-CTCCTCGGCTTCGATTCTC-3') and *oli5* (5'-CATTAAACCATAAC-GCATACATTTTC-3') were used. *Oli5* and *Oli9* were designed to anneal to the exon sequence either side of the single *CO* intron to prevent the amplification of contaminating DNA (Simon *et al.*, 1998). The position of the intron is marked in the primer sequence by a hyphen. To amplify the *APETALA2* cDNA as a control, primers *AP2 Oli3* (5'-CTCAATGCCG-AGTCATCAGG-3') and *AP2 Oli4* (5'-CATG-AGAGGAGGTTGGAAGC-3') were used. The resulting PCR products were fractionated on an agarose gel, Southern blotted onto Hybond N+ (Amersham, Little Chalfont, UK) according to the manufacturer's instructions and probed with the *CO* cDNA.

Primers used to analyse the *co-8* rearrangement

The following primers were used to identify and characterize the *co-8* rearrangement:

co25 (5'-TACTGTTGTGCAAATGG-3') and *co52* (5'-GGAACAGCC-ACGAAGCAAC-3') were used in the IPCR experiment to amplify the DNA adjacent to the deletion in *co-8*. *co17* (5'-ATGGATCATGTGGACTAG-3') anneals in the *CO* promoter and was used to first identify the inversion in *co-8*. *co74* (5'-GATGGGCTACGTATGCGGC-3') and *co75* (5'-GGACTA-AGCATATACGACATCTC-3') were designed to anneal to DNA brought adjacent to each side of the deletion in *co-8* by the inversion. In wild-type they anneal to DNA within P1 clone MP10.

Construction of transformation vectors

p35S::co3 was constructed by first isolating the CaMV 35S promoter as a 350 bp *Cla* I – *Hind* III fragment from pJ1762 (Guerineau *et al.*, 1992) and cloning it into these sites in

Analysis of CONSTANS 629

pBluescript. A 1.7 kb *Hind* III fragment containing the *co-3* genomic region, including the native CO polyadenylation sequences, was isolated from pco-3. *Hind* III cuts in this clone in the polylinker near the 3' end of the gene and also in the plant DNA 70 bp upstream of the ATG. This was cloned into the *Hind* III site adjacent to the 35S promoter and orientated correctly by restriction mapping. 35S::co3 was moved as a *Cla* I – *Bam* HI fragment into the binary vector pSLJ1711 (Jones *et al.*, 1992). p35S::CO was constructed in essentially the same way, as described by Onouchi *et al.* (2000).

Transformation of Arabidopsis

Landsberg *erecta* plants were transformed with the 35S::co-3 construct by floral dipping (Bechtold *et al.*, 1993; Clough and Bent, 1998). The *Agrobacterium* strain used was C58C1 pGV101 pMP90. Kanamycin-resistant transformants (T1 generation) were selected on 1/2 × Murashige and Skoog (MS) agar. Flowering time was measured in the T3 generation using lines homozygous for the T-DNA from several independent transformants.

Bombardment of onion bulb epidermal cells

From the inner layer of onion bulb, a peel of epidermis was taken and placed inside up on top of a 50 µl drop of liquid MS on a plate containing solid MS medium (Varagona *et al.*, 1992). The medium contained per litre, 4.3 g MS, 1 mg thiamine, 10 mg myo-inositol, 180 mg KH₂PO₄ and 30 g sucrose, the pH was adjusted to 5.7 with KOH. After autoclaving, 2.5 mg of amphotericin (in DMSO) was added to the medium. The onion epidermal layers were prepared just before bombardment. 20 µg of plasmid GFP(S65T):CO was precipitated onto gold particles and bombardment performed as described by McCabe and Christou (1993). After bombardment, onion cell layers were incubated at 20 °C for 5 h in complete darkness. To visualize the distribution of cellular DNA the onion peels were immersed in a solution of 0.1% (v/v) DAPI (Sigma-Aldrich, Dorset, UK) for 5 min. Subsequently, they were mounted in water and examined by epifluorescence microscopy (Nikon E-800, Nikon, Melville, NY, USA).

Plasmid construction

The GFP-vector pAVA121 was provided by Dr A.G. von Arnim (von Arnim *et al.*, 1998). This plasmid is based on the expression cassette of pRTL2 (Restrepo *et al.*, 1990) that contains a double 35S promoter from CaMV, the translational leader sequence from tobacco etch virus (TEV), and the 35S polyadenylation signal from CaMV. The GFP cDNA is a modified version of mGFP4 (Haseloff *et al.*, 1997) (GFP(S65T)), in which the serine 65 residue is substituted by a threonine, resulting in increased absorbance of blue light and reduced absorbance of UV light (Heim *et al.*, 1995). The CO cDNA was inserted in frame in the *Bgl*II restriction site of the C-terminus of GFP(S65T). The region corresponding to the CO C-terminus (Met304-Phe373) was amplified by PCR using the primers 5'TERCO (5'-CAA CTC GGA TCC ATG GAG AGA GAA GCC-3') and 3'TERCO (5'-AAT CAG ATC TTT CTT TTT GCC ACA GGA G-3'). The 5'TERCO primer introduces a *Bam*HI site before the first codon of the sequence (methionine 304) and the 3'TERCO primer introduces a *Bgl*II restriction site after the CO coding sequence. The PCR fragment was digested with *Bam*HI and *Bgl*II and cloned into the *Bgl*II restriction site of the vector pAVA121 resulting in an in-frame translational fusion at the C-terminus of

GFP. This fusion was called GFP(S65T):Cterm. The region corresponding to the first 303 amino acid residues was amplified by PCR using primers OLIGO2 (5'-TGA GGA TCC ATG TTG AAA CAA GAG AGT A-3') and C'-STOP (5'-CT GAG ATC TCA ACT GAG TTG TGT TAC T G-3'). Oligo2 maintains the *Bam*HI restriction site before the start codon of the CO gene and the reverse primer transforms the proline 302 codon (CCA) into a stop codon (TGA) as well as introducing a *Bgl*II restriction site after the stop codon. The amplified fragment was inserted at the 3' end of the GFP gene, as described previously for the CO C-terminus. This fusion was called (GFP(S65T):Nterm. The primers 5'TERCO and 3'TERCO were also used to amplify the DNA encoding the C-terminal region (Met304-Phe373) of CO from the mutants *co-5* and *co-7*. The PCR fragments were digested with *Bam*HI and *Bgl*II and cloned into the *Bgl*II restriction site of the vector pAVA121 (creating fusion proteins GFP(S65T):Co-5 and GFP(S65T):Co-7). All the PCR fragments were sequenced to check for PCR errors.

Acknowledgements

This work was funded by grants from the BBSRC and EC to G.C. S.R.H. was supported by an EMBO long-term fellowship, M.M.R.C. by a Ph.D. studentship (PRAXIS XXI/BD/3781/94) from Fundação para a Ciência e a Tecnologia, Portugal, and P.H.R. by the EC through the REGIA project.

References

- Arabidopsis Genome Initiative (2000) Analysis of the genome sequence of the flowering plant *Arabidopsis thaliana*. *Nature*, **408**, 796–815.
- von Arnim, A.G., Deng, X.-W. and Stacey, M.G. (1998) Cloning vectors for the expression of green fluorescent protein fusion proteins in transgenic plants. *Gene*, **221**, 35–43.
- Bechtold, N., Ellis, J. and Pelletier, G. (1993) In *Planta Agrobacterium* mediated gene transfer by infiltration of adult *Arabidopsis thaliana* plants. *C.R. Acad. Sci. Paris, Sciences de la Vie/Life Sci.* **316**, 1194–1199.
- Bellini, M., La Croix, J.-C. and Gall, J.G. (1993) A putative zinc binding protein on lampbrush chromosome loops. *EMBO J.* **12**, 107–114.
- Borden, K.L.B. (1998) RING fingers and B-boxes: zinc-binding protein–protein interaction domains. *Biochem. Cell Biol.* **76**, 351–358.
- Borden, K.L., Lally, J.M., Martin, S.R., O'Reilly, N.J., Etkin, L.D. and Freemont, P.S. (1995) Novel topology of a zinc-binding domain from a protein involved in regulating early *Xenopus* development. *EMBO J.* **14**, 5947–5956.
- Calmarca, S., Messall, S., Ballabio, A. and Mèroni, G. (1999) Functional characterization of the Opitz syndrome gene product (midin): evidence for homodimerization and association with microtubules throughout the cell cycle. *Human Mol. Genet.* **8**, 1387–1398.
- Chan, E.K.L., Hamel, J.C., Buyon, J.P. and Tan, E.M. (1991) Molecular definition and sequence motifs of the 52kD component of human ss-A/Ro auto-antigen. *J. Clin. Invest.* **87**, 68–76.
- Clough, S.J. and Bent, A.F. (1998) Floral dip: a simplified method for *Agrobacterium*-mediated transformation of *Arabidopsis thaliana*. *Plant J.* **16**, 735–743.
- Dean, C., Sjödin, C., Page, T., Jones, J.D.G. and anmd Lister, C. (1992) Behaviour of the maize transposable element Ac in *Arabidopsis thaliana*. *Plant J.* **2**, 69–81.

630 Frances Robson et al.

- Deng, X.-W., Matsui, M., Wei, N., Wagner, D., Chu, A.M., Feldmann, K.A. and Quail, P.H. (1992) COP1, an Arabidopsis regulatory gene, encodes a protein with both a zinc-binding motif and a G-beta homologous domain. *Cell*, **71**, 791-801.
- El-Husseini, A.E.D., Kwasnicka, D., Yamada, T., Hirohashi, S. and Vincent, S.R. (2000) BERP, a novel ring finger protein, binds to alpha-actinin-4. *Biochem. Biophys. Res. Comm.* **267**, 908-911.
- Goddard, A.D., Borrow, J., Freemont, P.S. and Solomon, E. (1991) Characterization of a novel zinc finger gene disruption by the t (15; 17) in acute promyelocytic leukemia. *Science*, **254**, 1371-1374.
- Grebencok, R.J., Pierson, E., Lambert, G.M., Gong, F.C., Afonso, C.L., Haldeman-Cahill, R., Carrington, J.C. and Galbraith, D.W. (1997) Green-fluorescent protein fusions for efficient characterization of nuclear targeting. *Plant J.* **11**, 573-586.
- Guerineau, F., Brooks, L. and Mullineaux, P. (1992) Effect of deletions in the cauliflower mosaic virus polyadenylation sequence on the choice of the polyadenylation sites in tobacco protoplasts. *Mol. Gen. Genet.* **228**, 141-144.
- Haseloff, J., Siemering, K.R., Prasher, D.C. and Hodge, S. (1997) Removal of a cryptic intron and subcellular localization of green fluorescent protein are required to mark transgenic Arabidopsis plants brightly. *Proc. Natl Acad. Sci. USA*, **94**, 2122-2127.
- Helm, R., Prasher, D.C. and Tsien, R.Y. (1994) Wavelength mutations and posttranslational autooxidation of green fluorescent protein. *Proc. Natl Acad. Sci. USA*, **91**, 12501-12504.
- Hope, I.A. and Struhl, K. (1986) Functional dissection of a eukaryotic transcriptional activator protein, GCN4 of yeast. *Cell*, **46**, 885-894.
- Inoue, S., Orimo, A., Hosoi, T., Kondo, S., Toyoshima, H., Kondo, T., Ikegami, A., Ouchi, Y., Orimo, H. and Muramatsu, M. (1993) Genomic binding site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. *Proc. Natl Acad. Sci. USA*, **90**, 11117-11121.
- Jones, J.D.G., Shlumukov, L., Carland, F., English, J., Scofield, S.R., Bishop, G.J. and Harrison, K. (1992) Effective vectors for transformation, expression of heterologous genes, and assaying transposon excision in transgenic plants. *Transgenic Res.* **1**, 285-297.
- Kardailsky, I., Shukla, V.K., Ahn, J.H., Dagenais, N., Christensen, S.K., Nguyen, J.T., Chory, J., Harrison, M.J. and Weigel, D. (1999) Activation tagging of the floral inducer FT. *Science*, **286**, 1962-1965.
- Keegan, L., Gill, G. and Ptashne, M. (1986) Separation of DNA binding from the transcription-activating function of a eukaryotic regulatory protein. *Science*, **231**, 699-704.
- Kobayashi, Y., Kaya, H., Goto, K., Iwabuchi, M. and Araki, T. (1999) A pair of related genes with antagonistic roles in mediating flowering signals. *Science*, **286**, 1960-1962.
- Koomneef, M., Hanhart, C.J. and van der Veen, J.H. (1991) A genetic and physiological analysis of late flowering mutants in *Arabidopsis thaliana*. *Mol. General Genet.* **229**, 57-66.
- Kurup, S., Jones, H.D. and Holdsworth, M.J. (2000) Interactions of the developmental regulator ABI3 with proteins identified from developing Arabidopsis seeds. *Plant J.* **21**, 143-155.
- Lagercrantz, U. and Axelsson, T. (2000) Rapid evolution of the family of CONSTANS LIKE genes in plants. *Mol Biol. Evol.* **17**, 1499-1507.
- Ledger, S., Dare, A. and Putterill, J. (1996) COL2 (Accession, L81119 and L81120) is a homologue of the Arabidopsis flowering time gene CONSTANS (PGR 96-081). *Plant Physiol.* **112**, 862.
- Ledger, S., Strayer, C., Ashton, F., Kay, S.A. and Putterill, J. (2001) Analysis of the function of two circadian-regulated CONSTANS-LIKE genes. *Plant J.* **26**, 15-22.
- Leonhardt, E.A., Kapp, L.N., Young, B.R. and Murnane, J.P. (1994) Nucleotide-sequence analysis of a candidate gene for Ataxia-Telangiectasia Group-D (ATDC). *Genomics*, **19**, 130-136.
- Lippuner, V., Cyert, M.S. and Gasser, C.S. (1996) Two classes of plant cDNA clones differentially complement yeast calcineurin mutants and increase salt tolerance of wild-type yeast. *J. Biol. Chem.* **271**, 12859-12866.
- Makino, S., Kiba, T., Imamura, A., Hanaki, N., Nakamura, A., Suzuki, T., Taniguchi, M., Ueguchi, C., Sugiyama, T. and Mizuno, T. (2000) Genes encoding pseudo-response regulators: insight into His-to-Asp phosphorelay and circadian rhythm in *Arabidopsis thaliana*. *Plant Cell Physiol.* **41**, 791-803.
- McCabe, D. and Christou, P. (1993) Direct DNA transfer using electric discharge particle acceleration (ACCELLTM technology). *Plant Cell Tissue Organ. Cult.* **33**, 227-236.
- Miki, T., Fleming, T.P., Crescenzi, M., Molloy, C., Blam, S., Reynolds, S. and Aaronson, S. (1991) Development of a highly efficient cDNA cloning system: application to oncogene isolation. *Proc. Natl Acad. Sci. USA*, **88**, 5167-5171.
- Miller, M., Kloc, M., Reddy, B.A., Eastman, E., Dreyer, C. and Etkin, L.D. (1989) x1gv7: a maternal gene product localised in nuclei of the central nervous system in *Xenopus laevis*. *Genes Dev.* **3**, 572-583.
- Mizukami, Y. and Ma, H. (1997) Determination of Arabidopsis floral meristem identity by AGAMOUS. *Plant Cell*, **9**, 393-408.
- Onouchi, H., Igono, M.I., Perilleux, C., Graves, K. and Coupland, G. (2000) Mutagenesis of plants over-expressing CONSTANS demonstrates novel interactions among Arabidopsis flowering-time genes. *Plant Cell*, **12**, 885-900.
- Patarca, R., Schwartz, J., Singh, R.P., Kong, Q.T., Murphy, E., Anderson, Y., Sheng, F.Y.W., Singh, P., Johnson, K.A., Guathagia, S.M., Durfee, T., Blattner, F. and Cantor, H. (1988) rpt-1, an intracellular protein from helper/inducer T cells that regulates gene expression of interleukin-2 receptor and human immunodeficiency virus type 1. *Proc. Natl Acad. Sci. USA*, **85**, 2733-2737.
- Peng, H.Z., Begg, G.E., Schultz, D.C., Friedman, J.R., Jensen, D.E., Speicher, D.W. and Rauscher, F.J. (2000) Reconstitution of the KRAB-KAP-1 repressor complex: a model system for defining the molecular anatomy of RING-B box-coiled-coil domain-mediated protein-protein interactions. *J. Mol. Biol.* **295**, 1139-1162.
- Potuschak, T., Stary, S., Schloegelhofer, P., Beker, F., Nejnskaia, V. and Bachmair, A. (1998) PRT1 of *Arabidopsis thaliana* encodes a component of the plant N-end rule pathway. *Proc. Natl Acad. Sci. USA*, **95**, 7904-7908.
- Putterill, J.J., Ledger, S.E., Lee, K., Robson, F., Murphy, G. and Coupland, G. (1997) The flowering time gene CONSTANS and homologue CONSTANS LIKE 1 exist as a tandem repeat on chromosome 5 of Arabidopsis. *Plant Physiol.* **114**, 396.
- Putterill, J., Robson, F., Lee, K., Simon, R. and Coupland, G. (1995) The CONSTANS gene of Arabidopsis promotes flowering and encodes a protein showing similarities to zinc finger transcription factors. *Cell*, **80**, 847-857.
- Raikhel, N. (1992) Nuclear targeting in plants. *Plant Physiol.* **100**, 1627-1632.
- Reddy, B.A., Etkin, L.D. and Freemont, P.S. (1992) A novel zinc finger coiled-coil domain in a family of nuclear proteins. *Trends Biochem. Sci.* **17**, 344-345.
- Redel, G.P. (1962) Supravital mutants of Arabidopsis. *Genetics*, **47**, 443-460.

Analysis of CONSTANS 631

- Restrepo, M.A., Freed, D.D. and Carrington, J.C. (1990) Nuclear transport of plant potyviral proteins. *Plant Cell*, **2**, 987-998.
- Robert, L.S., Robson, F., Sharpe, A., Lydiate, D. and Coupland, G. (1998) Conserved structure and function of the Arabidopsis flowering time gene CONSTANS in *Brassica napus*. *Plant Mol Biol.* **37**, 763-772.
- Robson, F. (1998) Characterization of CONSTANS an Arabidopsis gene that promotes flowering. PhD Thesis, Milton, Keynes, UK: The Open University/John Innes Centre.
- Samach, A., Onouchi, H., Gold, S.E., Ditta, G.S., Schwarz-Sommer, Zs, Yanofsky, M.F. and Coupland, G. (2000) Distinct roles of CONSTANS target genes in reproductive development of Arabidopsis. *Science*, **288**, 1613-1616.
- Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) *Molecular Cloning: A Laboratory Manual*, 2nd edn. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
- Schaffer, R., Ramsay, N., Samach, A., Corden, S., Putterill, J., Carre, I. and Coupland, G. (1998) The late elongated hypocotyl mutation in Arabidopsis disrupts circadian rhythms and the photoperiodic control of flowering. *Cell*, **93**, 1219-1229.
- Schultz, J., Copley, R.R., Doerks, T., Ponting, C.P. and Bork, P. (2000). SMART: a web-based tool for the study of genetically mobile domains. *Nucl. Acids Res.* **28**, 231-234.
- Schultz, J., Milpetz, F., Bork, P. and Ponting, C.P. (1998) SMART, a simple modular architecture research tool: Identification of signalling domains. *Proc. Natl Acad. Sci. USA*, **95**, 5857-5864.
- Simon, R., Igeno, I.M. and Coupland, G. (1996) Activation of floral meristem identity genes in Arabidopsis. *Nature*, **384**, 59-62.
- Soppe, W.J.J., Jacobsen, S.E., Alonso-Blanco, C., Jackson, J.P., Kakutani, T., Koornneef, M. and Peeters, A.J.M. (2000) The late flowering phenotype of *fwa* mutants is caused by gain-of-function epigenetic alleles of a homeodomain gene. *Mol. Cell*, **6**, 791-802.
- Strayer, C., Oyama, T., Schultz, T.F., Raman, R., Somers, D.E., Mas, P., Panda, S., Kreps, J.A. and Kay, S.A. (2000) Cloning of the Arabidopsis clock gene TOC1, an autoregulatory response regulator homolog. *Science*, **289**, 768-771.
- Takahashi, M., Inaguma, Y., Hiai, H. and Hirose, F. (1988) Developmentally regulated expression of a human 'Finger'-containing gene encoded by the 5' half of the ret transforming gene. *Mol. Cell. Biol.* **8**, 1853-1856.
- Tokunaga, C., Kuroda, S., Tatematsu, K., Nakagawa, N., Ono, Y. and Kikkawa, U. (1998) Molecular cloning and characterization of a novel protein kinase C-interacting protein with structural motifs related to RBCC family proteins. *Biochem. Biophys. Res. Commun.* **244**, 353-359.
- Tsuzuki, S., Towatari, M., Saito, H. and Enver, T. (2000) Potentiation of GATA-2 activity through interactions with the Promyelocytic Leukemia Protein (PML) and the t (15; 17) - generated PML-Retinoid Acid receptor \pm oncoprotein. *Mol. Cell. Biol.* **20**, 6276-6286.
- Unger, E., Parsons, R.L., Schmidt, R.J., Bowen, B. and Roth, B.A. (1993) Dominant-negative mutants of opaque2 suppress transactivation of a 22-kd zein promoter by opaque2 in maize endosperm cells. *Plant Cell*, **5**, 831-841.
- Varagona, M.J., Schmidt, R.J. and Raikhel, N.V. (1992) Nuclear localization signal (s) required for nuclear targeting of the maize regulatory protein Opaque-2. *Plant Cell*, **4**, 1213-1227.
- Vizir, I.Y., Anderson, M.L., Wilson, Z.A. and Mulligan, B.J. (1994) Isolation of deficiencies in the Arabidopsis genome by gamma-irradiation of pollen. *Genetics*, **137**, 1111-1119.
- Wagner, D., Sablowski, R.W.M. and Meyerowitz, E.M. (1999) Transcriptional activation of APETALA1 by LEAFY. *Science*, **285**, 582-584.
- Zou, J.T. and Taylor, D.C. (1997) Cloning and molecular characterization of an Arabidopsis thaliana RING zinc finger expressed preferentially during seed development. *Gene*, **196**, 291-295.

Based on Form PTO-1449 (3/90)				ATTY. DOCKET NO. 674538-2001		SERIAL NO. 09/732,348			
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT Choo et al					
				FILING DATE 12/07/00		GROUP 1614			
U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME			CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA								
FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER	DATE	COUNTRY			CLASS	SUBCLASS	TRANSLATION
	AB								
	AC								
	AD								
	AE								
	AF								
	AG								
	AH								
	AI								
	AJ								
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)									
	AK	Abstract by Putterill et al. (submitted herewith) from the 8 th International Meeting on Arabidopsis Research, June 25-29, 1997, Madison, Wisconsin, Abstract 3-58 available on the internet at www.arabidopsis.org/madison97/at97abs/imar_3-58.html							
	AL	Robson et al, The Plant Journal 28(6):619-631 (2001)							
	AM								
	AN								
	AO								
	AP								
	AQ								
	AR								
	AS								
EXAMINER					DATE CONSIDERED				
<p>* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>									

Based on Form PTO-1449 (3/90)				ATTY. DOCKET NO. 674538-2001		SERIAL NO. 09/732,348			
LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT Choo et al					
				FILING DATE 12/07/00					
						GROUP 1614			
U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME			CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA								
FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER	DATE	COUNTRY			CLASS	SUBCLASS	TRANSLATION
	AB								
	AC								
	AD								
	AE								
	AF								
	AG								
	AH								
	AI								
	AJ								
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)									
	AK	Abstract by Putterill et al. from the 8 th International Meeting on Arabidopsis Research, June 25-29, 1997, Madison, Wisconsin, Abstract 3-58 available on the internet at www.arabidopsis.org/madison97/at97abs/imar_3-58.html							
	AL	Robson et al, The Plant Journal 28(6):619-631 (2001)							
	AM								
	AN								
	AO								
	AP								
	AQ								
	AR								
	AS								
EXAMINER				DATE CONSIDERED					
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

PATENT
USSN 09/732,348
674538-2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Choo, et al.
Serial No. 09/732,348
Filed : December 7, 2000
For : REGULATED GENE EXPRESSION IN PLANTS
Examiner : Cynthia E. Collins
Art Unit : 1614


745 Fifth Avenue, New York, New York 10151

FACSIMILE

I hereby certify that this paper is being facsimile transmitted
to the Patent and Trademark Office on the date shown
below.

Thomas J. Kowalski, Reg. No. 32,147

Type or print name of person signing certification



Signature

January 17, 2003

Date of Signature

CHANGE OF ADDRESS


Commissioner for Patents
Washington, D.C. 20231
Sir:

It is respectfully requested that all communications from the USPTO be directed to the undersigned, at the addresses, and telephone and facsimile numbers, provided below.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP
Attorneys for Applicants

By:



Thomas J. Kowalski, Reg. No. 32,147
c/o FROMMER LAWRENCE & HAUG LLP
745 Fifth Avenue, NY, NY 10151
Tel 212-588-0800
Fax 212-588-0500
TKowalski@FLHLaw.com